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Zusammenfassung
Protenentherapie zur Behandlung von Tumorerkrankungen ist stark abhängig von der
Präzision des Protonenstrahls. Die Reichweite von Protonen unterliegt Unsicherheiten,
zum Beispiel verursacht durch die Positionierung des Patienten, durch die semi-empirische
Umwandlung von Röntgen-CT-Werten in das gewebespezifische Bremsvermögen (relativ zu
dem von Wasser), oder durch anatomische Veränderungen. Prompt-Gamma-Bildgebung
(PG) eröffnet die Möglichkeit, die Protonenreichweite in vivo zu beobachten, indem
Prompt-Gammas detektiert werden, die durch Kernrelaxation innerhalb des Strahlen-
gangs emittiert werden. Studien haben gezeigt, dass die Genauigkeit von PG von
verschiedenen Faktoren abhängt, zum Beispiel von der Strahlstatistik, der Gewebehetero-
genität, anatomischen Veränderungen und vom PG-Kamera Prototypen. Diese Effekte
werden beim konventionellen Protonen-Bestrahlungsplanungsprozess nicht berücksichtigt,
weshalb PG-Bildgebung noch nicht vollumfänglich möglich ist. In dieser Dissertation
werden diese Effekte untersucht, die sowohl die PG Emission als auch Detektion betreffen.
Ein neues Bestrahlungsplanungskonzept wird vorgeschlagen, das die PG-basierende in-vivo
Reichweitenverifikation berücksichtigt.
Im ersten Teil dieser Arbeit wird das Monte Carlo (MC) Simulationstoolkit Geant4 ver-
wendet um die Spot-by-Spot-Dosis, die PG Emission und die PG Detektion zu simulieren.
Dabei wird eine ideale Scoring-Ebene auerhalb des Targets verwendet (Phasenraum-
daten, genannt phsp Daten). Die MC Bestrahlungspläne wurden erstellt mit Hilfe einer
Forschungs-Softwareplattform, in der mit MC vorberechnete Nadelstrahlen (PB) mit dem
analytischen, Matlab-basierten Bestrahlungsplanungssystem (TPS) CERR kombiniert
wurden. Der Effekt der Protonenstrahl-Statistik auf die PG Genauigkeit wird zunächst un-
tersucht, indem lateral integrierte Profile der phsp Daten des selben PBs in verschiedenen
Szenarien verglichen werden. Die Ergebnisse zeigen, dass mindestens 1.35×108 Protonen
pro PB nötig sind, um eine PG Genauigkeit von 1mm zu erreichen. Zweitens wird die
Konformität zwischen der Dosis und der PG Emission (PG Dosiskorrelation) untersucht
und quantifiziert indem der 80%-distale Abfall und der Abfall der PG Emissionsprofile
verglichen wird mithilfe eines Machine Learning Mustererkennungsalgorithmus. Beim ur-
sprünglichen Bestrahlungsplan konnten nur wenige PBs aus dem Optimierungsprozess eine
ausreichende Statistik erreichen und nicht alle PBs hatten eine gute PG-Dosiskorrelation,
insbesondere solche mit dem Bragg-Peak in der Nähe von Gewebeheterogenitäten, z.B.
Luftkavitäten. In dieser Arbeit wird ein neues Bestrahlungsplanungskonzept vorgeschla-
gen, das PG Bildgebung berücksichtigt und wenige PBs verstärkt, basierend auf der
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PG-Dosiskorrelation, sodass sie eine ausreichende Statistik haben, während die Qualität
der Bestrahlung unverändert bleibt. Die neuen Bestrahlungspläne wurden verglichen
mit den ursprünglichen Bestrahlungsplänen basierund auf einer MC Simulation auf der
selben Computertomographie (CT) für 3 Kopf-Hals-Tumoren Patienten. Es wird gezeigt,
dass die neuen re-optimierten Bestrahlungspläne äquivalent sind zu den ursprünglichen
bezüglich der Dosisverteilung, der Verteilung des Dosis-gemittelten linearen Energietrans-
fers (LET) und der Robustheit gegenüber Verschiebungen/Reichweitenveränderungen,
und gleichzeitig die statistischen Bedingungen für ein zuverlässiges PG-Monitoring der
ausgewählten PBs erfüllen.
Der zweite Teil dieser Arbeit beschäftigt sich mit dem Effekt von inter-fraktionalen
anatomischen Veränderungen auf die Robustheit der PG-Dosiskorrelation. Dies wurde
erreicht durch eine 2D distale Oberfläche (Dosisoberfläche), die von einer 3D MC
Dosisverteilung der entsprechenden PBs abgeleitet wurde. Die Dosisoberfläche wurde
als Indikator für PBs genutzt, die stärker abhängig von anatomischen Veränderun-
gen waren. Mit Hilfe von CERR und Geant4, wurden die neuen re-optimisierten
Bestrahlungspläne basierend auf einer Kombination der Dosisoberfläche und PG-
Dosiskorrelations-Indikatoren vergleichen mit den ursprünglichen Bestrahlungsplänen auf
den CTs von 1 Kopf-Hals-Tumor und 1 Prostata-Karzinom Patienten zu 3 verschiedenen
Zeitpunkten. Die Verschiebung der Dosis und PG-Emissionsprofile auf verschiedenen CTs
und mit den selben PBs wurden verglichen um zu entscheiden ob ein gegebener PB für PG
Bildgebung verlässlich ist. Es wurde gezeigt, dass die re-optimisierten und ursprünglichen
Bestrahlungspläne vergleichbar sind im Sinne der Dosisverteilung und der Verteilung des
Dosis-gemittelten LET über alle CTs, während die Verschiebungsunterschiede zwischen
der Dosis und PG-Emission der vorgeschlagenen PBs innerhalb von 1 mm waren.
Der letzte Teil dieser Arbeit beschäftigt sich mit der realistischen Antwort einer Knife-edge
Slit PG Kamera, welche ein Kandidat ist für die erste klinische Reichweitenbestimmung
von PB scanning durch PG. Die Dosisverteilung und die PG Emission und Detektion
wurden simuliert mit REGistration Graphical User Interface (REGGUI) für die selben PBs
und die selben CTs (nur 2 Zeitpunkte wurden genutzt) aus dem zweiten Teil. Da diese Art
von PG-Kamera-Prototyp die korrekte PG Information zur Verfügung stellen soll für PBs
deren PG Abfall zentral im Blickfeld (FOV) der Kamera ist, wurde ein zweiter Indikator
untersucht basierend darauf, ob ein PB zentral im FOV liegt oder nicht. Dieser Indikator
wurde zusammen mit dem Indikator für PG-Dosiskorrelation und der Dosisoberfläche
untersucht. Die Dosis und PG Emission generiert durch REGGUI wurden zunächst
verglichen mit denen erstellt durch Geant4. Danach wurde das PG Detektionsprofil unter
verschiedenen Statistiken des selben PBs verglichen, um den Einfluss der Statistik auf
die PG Detektion mittels dieser PG Kamera zu untersuchen. Eine Genauigkeit von 0.8
mm konnte erreicht werden mit 2.00×108 Protonen. Als nächstes wurden Verschiebungen
der Dosis und PG-Emission verglichen und die Ergebnisse sind konsistent mit den
vorhergehenden Schlüssen. Danach wurden die PBs-of-Interest identifiziert basierend auf
allen drei Indikatoren und deren Dosis- und PG-Detektionsprofile auf verschiedenen CTs
wurden in diversen Szenarien verglichen. Abgesehen von zwei Ausnahmen, die durch
unvorhersehbare und vergleichsweise groe anatomische Veränderungen hervorgerufen
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wurden, sind alle PG Signale der meisten vorgeschlagenen PBs verlässlich zum Moni-
toring des Dosisabfalls, was bedeutet, dass der Verschiebungsunterschied zwischen der
Dosis und dem detektierten PG-Signal unter 2 mm ist. Im Gegensatz dazu wurde ein
Verschiebungsunterschied von bis zu 9.1 mm beobachtet für die abgelehnten PBs. Aus
diesem Grund sind diese Indikatoren sehr wertvoll zur Identifikation von verlässlichen PBs
für PG-basierte Protonen-Reichweitenverifikation.
Der Ansatz der PB-Verstärkung wird zudem verglichen mit anderen alternativen Ansätzen
der PB Aggregation, welche naheliegende PBs aggregieren um eine höhere Statistik zu
erhalten, für alle vorgeschlagenen Indikatoren. Beide Ansätze sind vergleichbar bezüglich
der Reichweitenverifikation, jedoch zeigt die PB-Verstärkung Vorteile im Sinne einer
garantierten Statistik, einer verbesserten lateralen Auflösung und einer verringerten
Reichweitenvermischung.
Mit den Ergebnissen in dieser Dissertation wurde zum ersten Mal eine PG-basierte
in vivo Protonen-Reichweitenverifikationsmethode integriert in den Protonen-
Bestrahlungsplanungsprozess, was möglicherweise zu zukünftigen Verbesserungen
der präzisen Protonen-Bestrahlung beitragen könnte.
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Abstract
Proton therapy for cancer treatment is highly affected by the accuracy of the proton beam
delivery. However, proton range has uncertainties caused by e.g. patient positioning along
with the semi-empirical conversion of the X-ray CT numbers into tissue stopping power
ratio (relative to water) and anatomical changes. Prompt gamma (PG) imaging provides
the possibility to monitor the proton range in vivo by detecting the prompt gammas emit-
ted by nuclei de-excitation in the beam path. Studies point out that the accuracy of PG is
affected by factors e.g. the beam statistics, tissue heterogeneity, anatomical changes and
the PG camera prototype. These effects are not considered in the conventional proton
therapy treatment planning process thus the PG imaging technique is not fully supported.
In this thesis, these effects are investigated at both the PG emission and detection level. A
new treatment planning concept accounting for PG-based in-vivo proton range verification
is proposed.
In the first part of this work, the Monte Carlo (MC) simulation toolkit Geant4 is employed
to simulate the spot-by-spot dose, PG emission and PG detection using an ideal scoring
plane outside the target (phase space data, called phsp data). The MC treatment plans
are made using a research computational platform, combining MC pre-calculated pencil
beams (PB) with the analytical Matlab-based treatment planning system (TPS) engine
CERR. The effect of the proton beam statistics to the PG precision is firstly investigated
by comparing the laterally integrated phsp data profiles of the same PB under different
statistics scenarios. The result shows that at least 1.35×108 protons per PB are needed
to achieve a PG precision of 1 mm. Secondly, the conformity between the dose and PG
emission (PG-dose correlation) has been investigated and quantified by comparing the 80%
distal dose falloff and the falloff of the PG emission profiles, which is identified using a ma-
chine learning based pattern recognition algorithm. In the initial treatment plan, only a
few PBs resulting from the optimization process can reach the wanted statistics and not all
PBs have good PG-dose correlation, especially those with their Bragg peak near tissue het-
erogeneity, e.g. an air cavity. In this work, a new treatment planning concept accounting
for PG imaging was proposed to boost a few PBs, selected based on the quantification of
PG-dose correlation, above the required statistics while maintaining the treatment quality.
The new treatment plans were compared to the initial treatment plans using MC simula-
tion on the same computed tomography (CT) for 3 head and neck cancer patients. The
new re-optimized treatment plans are shown to be equivalent to the initial ones in terms of
dose distribution, dose averaged linear energy transfer (LET) distribution and robustness
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with respect to translational changes/range variations, while fulfilling the set statistical
conditions for reliable PG monitoring for the selected PBs.
The second part of this work is dedicated to investigate the effect of the inter-fractional
anatomical changes on the robustness of PG-dose correlation. This is accomplished by
using a 2D distal surface (dose surface) derived from 3D MC dose distribution of the
corresponding PBs. The dose surface could be used as indicator of PBs more sensitive
to anatomical changes. Using CERR and Geant4, the new re-optimized treatment plans
based on the combination of the dose surface and PG-dose correlation indicators are com-
pared to the initial treatment plans on the CTs of 1 head and neck and 1 prostate cancer
patients at 3 different time points. The shift of the dose and PG emission profiles on
different CTs of the same PB are compared to evaluate if a given PB is reliable or not, in
terms of PG imaging. The re-optimized and the initial treatment plans are shown to be
comparable in terms of dose distribution and dose-averaged LET distribution on all CTs,
while the shift differences between the dose and PG emission of the recommended PBs are
within 1 mm.
The last part of this work focuses on the realistic response of a knife-edge slit PG camera,
which is under investigation in the first clinical PG based proton range verification research
for PB scanning. The dose distribution as well as the PG emission and detection are simu-
lated using REGistration Graphical User Interface (REGGUI) for the same PBs and same
patients CTs (only 2 time points are used) employed in the second part. As this kind of
PG camera prototype is supposed to provide correct PG information for PBs whose PG
falloffs are centered in the field of view (FOV) of the camera, another proposed indicator,
identifying whether a given PB is centered in the FOV or not, is investigated together
with the PG-dose correlation and dose surface indicators. The REGGUI generated dose
and PG emission are firstly compared to those generated by Geant4. Secondly, the PG
detection profile under different statistics for the same PB are compared to investigate the
effect of the statistics to the PG detection using this PG camera. A precision of 0.8 mm
can be achieved using 2.00×108 protons. Next, the shifts of the dose and PG emission are
compared and the result is shown to be consistent to the previous findings. Then, the PBs
of interest are identified by all the three indicators and their dose and PG detection profiles
on different CTs are compared accounting for different scenarios. Besides two exceptions
caused by unpredictable and comparably large anatomical changes, the PG signals of most
of the PBs recommended are proven to be reliable for dose falloff monitoring, i.e. the shifts
difference between the dose and detected PG signal are within 2 mm. In contrast, a shifts
difference up to 9.1 mm has been observed for the counter-indicated ones. Hence, these
indicators are valuable to be used to identify and recommend reliable PBs for PG based
proton range verification.
The PB boosting approach is compared to the other alternative approach of PB aggrega-
tion, which aggregates nearby PBs to achieve high statistics, for all the indicators proposed.
Both approaches are comparable in terms of range verification but the PB boosting shows
advantages in terms of guaranteed statistics, improved lateral resolution and reduced range
mixing.
With the results of this thesis, the PG based in-vivo proton range verification method is
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integrated in the proton treatment planning process for the first time, potentially con-
tributing to a future improvement of precise proton delivery.
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Chapter 1
Introduction and motivation
1.1 Introduction of proton therapy
Cancer is a group of diseases involving abnormal cell growth with the potential invasion
to adjoining parts of the body. The mechanisms stem from inherited genetics and genetic
mutations caused by environment (e.g. pollution) and lifestyle (e.g. tobacco and alcohol).
According to (Ferlay et al. 2019) there were an estimated 18.1 million (95% confidence
interval: 17.5-18.7 million) new cancer cases and 9.6 million (95% confidence interval: 9.3-
9.8 million) deaths from cancer worldwide in 2018.
Treatment of cancer encompass one or more modalities among e.g. surgery, chemother-
apy, immunotherapy and radiotherapy (RT). Radiotherapy plays an essential role in cancer
management with around 50% patients receiving RT at a certain point of their treatment
(Baumann et al. 2016).
The earliest roots of the medical application of radiation go back to the discovery of X-rays
in 1895 by Wilhelm Rontgen, which was then quickly followed by the discovery of natural
radioactivity and the isolation of radium in 1898 by Marie Curie. Though the hazards of
radiation exposure were initially not fully understood and little protection was used until
the 1920s (Matanoski et al. 2001), radium was believed to have wide curative powers and
radiotherapy was applied to many diseases.
In the following period, radiotherapy was continuously advanced to treat patients affected
by deep seated tumors, to overcome the limited penetration depth of X-rays from X-ray
tubes or alpha radiation from Radium. Thus, since the 1950s RT with external beams
(teletherapy) has evolved to higher (> 1 MeV) photon energies from radioactive sources
(e.g, 60Co) or produced with accelerators, to deliver the treatment starting from an external
radiation source at a certain distance from the patient surface. Additionally, radioactive
sources of shorter range radiation (e.g., low energy photons and electrons) can be used
for internal/interstitial therapy like radionuclide therapy and brachytherapy, where the
radiation source is placed at contact with or inside the patient targeting the organ with a
tumor.
Nowadays conventional radiotherapy of deep-seated targets typically uses high energy (6-
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20 MeV) X-rays generated via Bremsstrahlung from electron linear accelerators (LINACs).
Modern photon therapy includes possibilities to rotate (even continuously) the radiation
beam around the patient with intensity modulation. Despite these technological advances,
including also forms of image guidance to monitor the patient anatomy at the treatment
site, photons are limited by the physics of their depth dose (average energy absorbed per
unit mass) distribution, resulting in a continuous exponential attenuation after an initial
build-up maximum at a shallow (up to few centimeters) depth. To overcome these limi-
tations, heavy charged particles like protons can be regarded as an advanced form of RT,
which is meanwhile widely developed and used in state-of-the-art centers. It was in 1946
that Robert Wilson suggested that energetic protons could be an effective RT treatment
method (Wilson 1946). In his seminal work, he anticipated the therapeutic benefits of the
increased energy deposition of protons and heavier ions at the end of their path, owing to
the earlier findings of (Bragg & Kleeman 1904) with the ionization of alpha particles from
Ra in air, hence being referred to as Bragg peak. In 1954 the first proton therapy treatment
was performed with particle accelerators for physics research in Lawrence Berkeley Labo-
ratory (Tobias et al. 1958). Later in 1989, the first hospital-based proton therapy center,
which was a low energy cyclotron center for ocular tumors, opened at the Clatterbridge
center for oncology in the UK, followed in 1990 by the dedicated synchrotron based center
for deep seated tumours at the Loma Linda university medical center in Loma Linda, US.
The creation of a dedicated hospital-based proton facility was the milestone motivating
the expansion of facilities and patient treatments around the world, which gathered the
attention of the radiation oncology community (Das & Paganetti 2015). By November
2019 there are about 91 active facilities providing treatments using protons and meanwhile
13 with carbon ions, some of which are combined facilities for both carbons and protons,
all over the world (PTCOG 2020).
As already recognized in the seminal work of Robert Willson, one of the most important
advantages of using protons (or heavier ions) for radiotherapy is that the energy deposition
of energetic (> 1 MeV/u) heavy charged particles is inversely proportional to their squared
velocity, causing a dose deposition maximum, so-called Bragg peak, at the end of the beam
penetration depth, i.e. the range. By changing the initial beam energy and modulating
the proton fluence it is possible to overlap multiple Bragg peaks, resulting in a so-called
spread-out Bragg peak (SOBP) for good dose coverage to the target volume already with a
single beam direction (figure 1.1). More beam portals including fluence modulation can be
then used to further enhance target dose and spread the entrance dose over larger volumes
as done with photons, but due to the superior physical selectivity only 2-3 proton treat-
ment fields are typically sufficient compared to modern intensity-modulated radiotherapy
(IMRT) (Bortfeld 2006) and volumetric modulated arc therapy (VMAT) (Teoh et al. 2011),
with considerably reduced normal tissue exposure.
The clinical exploitation of the protons Bragg peak for radiotherapy highly depends on
the accuracy of the calculation of the proton range so that the planned dose is delivered in
the target while the dose delivered in the healthy tissue is minimized. It can be imagined
that high dose might be delivered in the healthy tissue while the target volume would not
receive the prescribed dose if the proton range is different from the prediction.
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Figure 1.1: Depth dose distribution in water for a photon beam (red), mono-energetic
proton beams (solid blue) and their resulting SOBP (dash blue). The photon dose shows
a build-up maximum close to the entrance and afterwards decreases with the penetration
depth. For protons, the dose increases with depth and reaches a narrow maximum, called
Bragg peak, near the end of the profile in correspondence of the beam range. By overlapping
multiple proton beams, the SOBP is created to cover the extended tumour target volume
with still acceptable entrance dose proximal to and no exit dose distal to the tumour (Levin
et al. 2005).
In practice, the proton beam range exhibits non-negligible (typically up to 3%) uncer-
tainties in the patient model used for treatment planning, due to e.g. the semi-empirical
conversion of the X-ray computed tomography (CT) numbers into tissue stopping power
ratio (relative to water), along with patient positioning errors and anatomical changes in
the typically fractionated course of therapy over several weeks. These factors will be further
discussed in chapter 2. To mitigate the deleterious effect of the proton range uncertainties,
practitioners typically introduce generous safety margins around the target volume and
prefer conservative beam directions avoiding to stop the beam in front of radiosensitive
targets, thereby not fully exploiting the sharp dose gradients enabled by proton beams. To
overcome such limitations, researchers have proposed and investigated over the last two
decades various methods to measure and assess the proton range in-vivo, e.g. via positron
emission tomography (PET), which detects the pairs of annihilation gamma rays following
the β+ nuclear decay of irradiation induced positron emitters (Kubota 2001).
Another promising approach is prompt gamma imaging (PG), which is the main topic of
this thesis work. PG detection for in vivo proton range verification was firstly proposed
by (Stichelbaut & Jongen 2003) and then experimentally demonstrated in first phantom
studies by (Min et al. 2006) and in first clinical investigations by (Richter et al. 2016, Xie
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et al. 2017). Inelastic interactions between the incoming protons and the tissue nuclei
occur along the beam path until 2-3 mm before the Bragg peak (depending on the energy
threshold of the involved nuclear reactions), thus the PG emission has been found to be
well correlated with the distal dose falloff (Knopf & Lomax 2013). Besides, PG is emitted
within less than nanoseconds after the nuclear interaction, making a real-time proton range
verification possible.
1.2 Motivation of this work
Several studies show that the precision of the PG range verification depends on the statistics
(i.e., number of particles) of the incident proton beam (Xie et al. 2017, Draeger et al. 2018).
With current detector systems, more than 108 protons are needed to generate smooth PG
profiles. Furthermore, the accuracy of the PG-based range retrieval could be affected by
tissue heterogeneities, potentially spoiling the correlation of the PG signal to the dose de-
livery (Janssen et al. 2014, Priegnitz et al. 2015, Schmid et al. 2015). Those effects are
not considered in traditional proton therapy treatment plans (TP, see chapter 2) as the in
vivo proton range verification is not taken into account at the stage of planning. The goal
of this thesis is to investigate and quantify the effect of statistics, tissue heterogeneities as
well as the response of a real PG camera (Xie et al. 2017) on the PG range verification
accuracy and propose a new treatment planning concept accounting for those effects, so
that the statistics of few selected and so-called PG-friendly pencil beams (PBs) fulfills the
requirement to enable a more reliable treatment monitoring.
This thesis is organized as follows:
Chapter 2 reviews the fundamental aspects of the physics of proton therapy as well as the
sources of the proton range uncertainties. A brief review of the start-of-the-art in-vivo
proton range verification methods, i.e. PET, ionacoustics and PG, is presented.
Chapter 3 then introduces different prototypes for PG imaging and addresses the effect of
beam statistics and tissue heterogeneities on the conformity between the PG signal and
dose.
The materials and methods used in this study are described in chapter 4, including the
Monte Carlo simulation toolkit Geant4 (Agostinelli et al. 2003) extensively used for particle
transport and interaction, the treatment planning system CERR (Deasy et al. 2003, Resch
et al. 2017), the REGGUI platform (Janssens et al. 2009, Kurz et al. 2015) for analytical
modeling of dose and PG emission along with the PG camera detector response, and basic
concepts of machine learning employed for pattern recognition of the PG signal falloff in
the subsequent chapters.
Chapter 5 presents the original investigations of this work based on dose distributions and
PG emission data generated by detailed Monte Carlo simulations using Geant4 on the
basis of clinical patient CT datasets obtained from the LMU University Hospital. The first
part of this study investigated and quantified the correlation between the profiles of the
dose and PG (PG-dose correlation) by comparing their falloff distributions. A new TP
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concept was then proposed to boost a few PBs (based on the PG-dose correlation) above
the needed statistics, and tested using the research treatment planning engine CERR. The
re-optimized TP using such a PB boosting method is compared to the initial TP as well
as to the alternative PB aggregation approach introduced in the literature to overcome
PG statistics limitations without modifying the planning process (Tian et al. 2018, Tian
et al. 2020). The second part of this work focuses on the robustness of the PG-dose cor-
relation in presence of anatomical changes. The effect of the tissue heterogeneity on the
robustness of the PG-dose correlation is quantified by using a 2D distal surface derived
from 3D dose distributions of the PB. This new indicator is combined with the PG-dose
correlation. The new TP and new indicators are evaluated using the same approaches as
those used in the first part of the work, however considering patient CT data acquired at
different time points to include the effect of anatomical changes.
Chapter 6 studies how the previous results at emission are influenced by the response of a
real PG camera, for which the measurement is found to be affected by the relative position
of the PG falloff within the camera field of view. By employing a camera positioning indi-
cator, the PB selection indicators introduced in chapter 5 at emission are further expanded
to account for the detection process. For this study, the REGGUI platform is used, thus
augmenting the application of the new proposed approach with analytically generated PG
data at emission and detection, the latter including (as in real measurements) or not (as in
ideal analytical calculations) effects of counting statistics. Using the same clinical datasets
of chapter 5 with 2 CTs per patient, one ideal and two realistic PG detection scenarios are
compared and discussed for the methods of PB boosting proposed in this work and the
PB aggregation proposed in the literature. In the last chapter, a summary and outlook of
this PhD thesis work is presente
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Chapter 2
Theory background
2.1 Physics of proton interactions in matter
2.1.1 Energy loss rate, linear energy transfer, dose and proton
range
The total stopping power of protons (shown in figure 2.1) consists of electronic, nuclear and
radiative stopping power. For proton therapy, the radiative stopping power is negligible
and the nuclear one is only relevant below ∼10 keV/u, hence also negligible. The electronic
stopping power is described by the well-known Bethe-Bloch equation (valid only for energies
higher than 1 MeV/u):
Sel
ρ
= −4πNAre2mec2
Z
A
z2
β2
[ln
2mec
2γ2β2
I
− β2 − δ
2
− C
Z
] (2.1)
in which Sel is the linear electronic stopping power, which describes the average rate at
which protons lose energy dE per unit path length dx due to inelastic interactions with
the atomic electrons:
Sel =
dE
dx
[MeV cm−1] (2.2)
and where ρ is the density of the material, NA is the Avogadro number, re is the classical
electron radius, me is the electron mass, z is the charge of the particle (z=1 in the case
of proton), Z is the atomic number of the medium, A is the atomic mass number, c is the
speed of light, β = u/c where u is the velocity of the incident particle, γ = (1 − β2)−1/2
is the Lorentz factor, I is the mean excitation energy of the medium and C is the shell
correction term.
When the protons slow down, i.e. β is comparable to the velocity of the orbital electrons,
the Bethe-Bloch equation is no longer valid to predict the stopping power. In this region,
so-called Lindhard region, the energy loss is proportional to the β, and can be described
by the model of Anderson and Ziegler (Ziegler et al. 1985).
The dose (Gy) can be defined by the average energy dE (J) absorbed per unit mass dm
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(kg):
dose =
dE
dm
(2.3)
For heavy charged particles and under the assumption of secondary electrons equilibrium,
this can be linked to the particle fluence spectrum times the mass stopping power (i.e.
stopping power divided by the density), integrated over the entire energy range:
dose =
∑
i
∫
ΦE,i
ρ
(
dEi
dx
)dE (2.4)
where the ΦE,i = dΦi/dE is the fluence spectrum of all primary and secondary i-th heavy
charged particles (mostly protons).
The linear energy transfer (LET) (L∆, keV/µm), depending on the material as well as the
type and energy of the incident charged particle, is given by:
L∆ =
dE∆
dx
(2.5)
where dE∆ is the mean energy lost due to electronic interactions in traversing the distance
dx, minus the kinetic energies in excess of ∆ of all electrons released by the incident particle.
The LET L∆ can also be calculated by: L∆ = Sel − (dEke,∆/dx) in which the dEke,∆ is
the mean sum of the kinetic energies, larger than ∆, of all the electrons released by the
incident charged particle in traversing a distance of dx (ICRU90 2016). When the ∆ is
set to infinity, the LET would be equivalent to Sel (ICRU90 2016) and be regarded as an
indicator of radiation quality which affects the relative biological effectiveness (RBE) of
the radiation (Hall 2000, Abolfath et al. 2017). RBE is defined by:
RBE =
Di
Dγ
(2.6)
where Di and Dγ are the absorbed dose of the incident particle beam and photon radiation
that causes the same amount of biological damage, respectively (Laramore et al. 2013).
As shown in simulation (figure 2.1 and 2.2), the stopping power of protons increases
dramatically with decreasing energy until a maximum value and then decreases again in
the very low-energy region where the Bethe-Bloch formula ceases its validity, thus being
responsible for the formation of the Bragg peak toward the maximum proton penetration
depth (cf. figure 2.2 left). Consequently, high energy is delivered at the Bragg peak where
the LET also reaches high value (figure 2.2 right), enabling proton beams to deliver high
dose with comparably high RBE (Hall 2000) in the desired region while leaving low dose
in the beam path, i.e. healthy tissue in the case of radiotherapy. The average length
traveled by protons slowing down from the initial kinetic energy E0 to 0 is described by
the so called continuous slowing down approximation range (RCSDA), defined by:
RCSDA =
∫ 0
E0
− dE
S(E)
(2.7)
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Figure 2.1: Stopping power of protons in water as a function of the kinetic energy made
using NIST data, last updated in July 2017 (Berger et al. 2017).
where S(E) is the stopping power calculated as a function of the kinetic energy E. However,
due to scattering effects (cf. section 2.1.2), the actual mean depth penetrated by protons in
the incident direction, called projected range Rmf , is shorter than RCSDA. This is described
by a ratio called detour factor Rmf/RCSDA.
While penetrating in matter the incident protons spread in the position and momentum
phase space due to the stochastic nature of the energy loss process, of which the stopping
power only represents the mean value. This spread causes a small variation of the range
of individual particles around the mean range value, so called range straggling, which
increases with increasing penetration depth (cf. figure 2.2). In practical applications in
Figure 2.2: Left: Bragg peak of protons in water (depth given in millimeters) for different
incident energies based on simulation and measurement data (Ivanchenko et al. 2014).
Right: dose averaged LET (LETd) distribution as well as the corresponding Bragg peak of
a 250 MeV proton beam (Chen & Ahmad 2011).
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proton therapy, as well as in this work, the proton range is defined by the 80% distal falloff
of the laterally integrated depth dose profile, which is found to be less sensitive to such
dependencies as range straggling and initial beam momentum spread.
2.1.2 Coulomb scattering
Protons are scattered by various Coulomb interactions with electrons and nuclei in the
beam path. The global effect is called multiple Coulomb scattering (MCS). Due to the
mass ratio, the Coulomb interaction with nuclei is the dominant scattering mechanism.
This effect in a target can be described by the Moliere theory:
f(θ) =
1
4πθM
2
∑
k
fk(θ′)
Bk
(2.8)
where f(θ) is the probability distribution function of the scattering angle θ, θM is the
characteristic MCS angle, θ′ = θ/
√
2θM and B is the logarithm of the effective number of
collisions in the target. For protons, the lateral scattering increases for thick targets and
target materials with high atomic number.
According to the central limit theorem, the probability distribution of the deflection angle
of the incident proton in a thick material is nearly Gaussian as the result of numerous
small random deflections with a width (standard deviation) given by (Highland 1975):
σθ =
17.5MeV
βpc
√
L
Lrad
[1 + 0.038ln(
L
Lrad
)] (2.9)
where L is the total mass thickness, Lrad ∼ Z−2 is the radiation length. The lateral multiple
Coulomb scattering increases for thick targets and high Z materials while decreases with
increasing incident energy according to the factor of βpc.
The analytical calculation of the MCS effect on the dose distribution is difficult, hence this
is typically addressed using Monte Carlo (MC) simulations or empirical parameterizations
in treatment planning systems, which also account for the additional low-dose tails resulting
from nuclear interactions (cf. section 2.1.3), as described e.g. in (Bellinzona et al. 2015).
2.1.3 Nuclear interactions
Incident protons can also interact with atomic nuclei via the nuclear force, resulting in a
reduction of the primary fluence. The target can break up, be excited, or yield a particle
transfer reaction. The following function can be used to describe the probability that an
incident proton is not having a nuclear interaction with the target atoms:
P (x) = e
− x
λmfp (2.10)
where the λmfp is the so-called mean free path λmfp = A/(NAσρ), A is the atomic mass
number, σ is the cross section of nuclear interaction and ρ is the density. An example of
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Figure 2.3: Nonelastic nuclear cross section as a function of proton energy. The closed and
open circles describe the interaction with the carbon and oxygen target nuclei, respectively
(Paganetti 2018).
dependence of the nonelastic nuclear cross section on typical constituents of the human
body is shown in figure 2.3.
In the case of proton therapy, the reaction of an incident proton hitting an atomic nucleus
in the beam path can be generally described by the following stages:
Intra-nuclear cascade
Assuming that the incident particle interacts with quasi-free nucleons within
the nucleus, this model is implemented by (Bertini et al. 1974) for the dynamic
part of the reaction. Protons and neutrons have momentum and binding energy
following the Fermi gas model and the semi-empirical mass formula (Battistoni
et al. 2016). According to the total cross section and the nucleon density, the
path length for the projectile can be computed. The type and momentum of
the striking particle and the target are determined when the nuclear interaction
occurs. In the final state particles are treated as the primary and transported
through the nucleus, producing the cascade when the assertion of the Pauli
Exclusion Principle and the incident energy is higher than the threshold (Ferrari
& Sala 1998). The secondary particles can scatter or escape and through the
coalescence mechanism not only protons and neutrons but also light nuclear
fragments can be emitted, depending on the energy. Hence, protons, neutrons
and other nuclear fragments can be generated (Ribansky et al. 1973, Blann
1983). There are also other available models, e.g. the binary cascade model
(Bertini et al. 1974) and the quantum molecular dynamics model (Sorge et al.
1989), which is the most comprehensive hadronic inelastic model not simulating
nucleon-nucleon collision but a more collective effect.
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Pre-equilibrium
When the energies of the particles of the cascade are lower than the energy
threshold of a few tens of MeV but the nucleus is not in thermal equilibrium, the
interactions are modeled using a semi-classical approach where nuclear collisions
originate holes in the Fermi sea that represent the excited nucleons (Griffin
1966). Particles are emitted under different probabilities for each step. The
residual nucleus stays in equilibrium with some excitation energy shared among
the remaining nucleons (Battistoni et al. 2016).
De-excitation
Different nuclei then de-excite in different ways, depending on the mass. For
heavy nuclei (Z > 65), not considered in proton therapy, the main mechanism
is the fission of the excited nucleus into two fragments. For other nuclei, light
particles, which have kinetic energies of a few MeV, would be emitted from the
excited nuclei, according to the nuclear evaporation approach (Weisskopf 1937).
In the so-called Fermi-breakup model proposed by (Fermi 1950), the excitation
energy may be above the binding energy of some fragmentation channels, lead-
ing to the split of the nucleus into smaller fragments. In the end, gamma
rays are released from the remaining excited nuclei, providing the possibility
to monitor the range of the incident protons (Stichelbaut & Jongen 2003, Min
et al. 2006).
The absorbed depth dose curve is affected by the nuclear interactions. There is a consider-
able energy and tissue dependent reduction in the primary proton fluence and production
of secondary particles that can have a relevant contribution to the total energy deposition.
The contribution of nuclear reactions for proton beams in water is about 10% for 150 MeV
and up to 20% for 250 MeV (Malmer 2001). Low-energy secondary particles are emitted
isotropically in the centre-of-mass frame of the mother nucleus while the high-energy ones
are originated mostly in the intra-nuclear cascade and pre-equilibrium stage and are emit-
ted in the forward direction. Secondary emissions (e.g. de-excitation photons) are highly
relevant to monitor the proton range in vivo, as investigated in this thesis.
2.2 Beam delivery and treatment planning in proton
therapy
Protons can be accelerated by cyclotrons, synchrotrons or synchrocyclotrons, more details
can be found in the work of (Owen et al. 2015).
There are two approaches to deliver dose to the target tumor using external beams, i.e.
proton beams in this work.
In passive spreading techniques, the quasi mono-energetic proton beam provided by the
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accelerator is spread laterally and longitudinally so that the dose is delivered homoge-
neously in the target. This is the so-called spread out Bragg peak (SOBP). Typically, a
system consisting of scatterers with different complexity is used for lateral spreading, while
the longitudinal range modulation is achieved by using either a stationary absorber (for
small modulation), or a rotating absorber of an appropriately tailored profile (range mod-
ulator wheel) or plates of variable thickness [Schippers, 2015]. To deliver the dose in the
assigned target volume, a patient specific combination of collimators and compensators is
used (figure 2.4). This technique is limited by the neutron production due to the additional
materials along the beam path and by the poor conformation in the proximal part of the
target. The other one is a much more modern technique, named active scanning. The
Figure 2.4: Left: Schematic setup of passive spreading techniques, in which the proton
beam is modified using a tumour specific collimator to deliver the required dose in the
target. Right: a typical SOBP can be achieved by a weighted superposition of elementary
Bragg peaks in the desired range of depths (Bortfeld & Schlegel 1996).
proton beam is deflected and steered by dipole magnets to scan the target volume voxel by
voxel (see figure 2.5). The penetration depth of the Bragg peak is adjusted by varying the
energy of the beam (at the accelerator level in synchrotons or immediately after extraction
in cyclotron-based systems). Compared to the passive spreading technique, this method
shows advantages in terms of the proximal and distal dose conformity as well as reduced
neutron production. Besides, this approach does not need a patient specific hardware and
the protons are used in a more efficient way.
More recently, an advanced type of treatment planning with active scanning delivery,
called intensity-modulated-particle-therapy (IMPT), has been well-developed and adopted
worldwide (Rehman et al. 2018). In IMPT, various beam intensities resulting in highly
heterogeneous dose distributions per field are generated intentionally in comparison to tra-
ditional ion beam therapy, where uniform dose distributions per field were delivered to
the patient. This allows the IMPT technique to maximally exploit the degrees of freedom
of the dose optimization process for either a final homogenous dose distribution (for the
sum of the treatment fields), or to deliver varying radiation dose in selected target regions
(Schlegel 2006).
To determine the energies, positions and intensities of the individual pencil beams (PB)
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Figure 2.5: In the proton beam active scanning system, individual pencil beams are de-
flected by two orthogonal magnetic fields (dipoles) to scan all the voxels (3D grids) of the
target. The intensity, direction and incident energy of each PB can be varied while no
compensator, collimator, scatter foil or range shifter is needed.
used in IMPT, a treatment planning system (TPS) is needed to find the solution achieving
the dose distribution closest to the set prescription. The main goal is to deliver the intended
level of dose covering (typically homogenously) the target volume, while minimizing the
dose delivered in healthy tissue and preserving special constraints on radiosensitive organs,
so called organs at risk (OARs).
Generally, to make a treatment plan (TP), the patient X-ray computed tomography (CT)
and the contours of clinically relevant structures are imported into the system. The CT
numbers are in Hounsfield scale unit (HU):
HU = 1000
µ− µwater
µwater − µair
(2.11)
where µ, µair and µwater are the linear attenuation coefficients of the corresponding mate-
rials, air, and water, respectively. HU values for materials e.g. air, water and soft tissue
are -1000, 0 and between 100-300, respectively (Feeman 2010).
In radiotherapy, the gross, palpable, visible or clinically demonstrable location and extent
of the malignant growth is called gross tumour volume (GTV). The clinical target volume
(CTV) includes a GTV and / or local subclinical spread of disease at a certain probability
level that must be treated. The planning target volume (PTV) used for TP contains the
CTV and an additional margin to account for the different types of variations and uncer-
tainties (Jones 1994). The prescription dose distribution Dpre,j (here j is the identifier of
voxels) is set based on the clinical goal in the PTV, along with the dose constraints in
the OARs. The dose distribution Di,j of all available individual PBi is calculated using
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a pencil beam algorithm. The treatment plan is then optimized by minimizing the cost
function which describes the dose difference between the prescription and the treatment
plan. An exemplary cost function in the TPS (CERR, cf. chapter 4) used in this thesis is:
c(w) =
∑
j
pj(w ·Di,j −Dj,pre)2 (2.12)
where w is the weight vector, i.e. the numbers of protons of all individual PBs in unit of
106, pj is the penalty factor for voxel j. In this study pj is set to 10000 for voxels in the
PTV, while it is set to 10 for voxels in the OARs.
There are different software options for treatment planning algorithms. In this work, a
particle extension of the research TPS CERR (A Computational Environment for Radio-
therapy Research) (Deasy et al. 2003, Schell & Wilkens 2010, Resch et al. 2017) is used to
create treatment plans. More details are presented in chapter 4.
2.3 The challenge of proton range uncertainties
One of the main advantages of proton therapy is the inverse energy deposition along the
beam path enabling highly conformal dose delivery to the tumor and low toxicity rate in
the healthy tissue (cf. chapter 1). On the other hand, the treatment accuracy is highly
sensitive to potential differences between the actual dose delivery and the dose predicted
by the TPS, especially due to uncertainties in the location of the Bragg peak within the
patient, related to the proton beam range (see figure 2.6).
Figure 2.6: Schematic illustration of the effect of range uncertainty on the treatment
delivery. The healthy tissue and the target, i.e. tumor, are represented by the red and
green rectangle, respectively. In the TP, the Bragg peak of one PB is predicted to be
delivered in the tumor (green profile). If this PB is affected by proton range uncertainty,
i.e. the actual dose delivery changes to the red profile, most of the dose would be delivered
in the healthy tissue instead of the target.
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2.3.1 Sources of proton range uncertainties
In clinical proton beam therapy, non-negligible proton range uncertainties that can under-
mine the intended treatment accuracy are caused by many factors, which can be classified
into two sources: treatment plan and treatment delivery.
Treatment plan
The TP is made using the X-ray CT scans of the patient, expressed in HU
scale. Proton range uncertainties can be caused by not only the noise gener-
ated due to CT artefacts and beam hardening (Paganetti 2012), but also the
semi-empirical conversion of the CT numbers into proton stopping power ratio
in tissue relative to water (Schaffner & Pedroni 1998), leading to proton range
inaccuracies of ca. 1-3% (Schaffner & Pedroni 1998), or even more. Analytical
algorithms are typically used for dose calculation in conventional TPSs. The
dose calculation mostly determines the proton beam range based on the water
equivalent thickness of the patient, neglecting the position of heterogeneities
relative to the Bragg peak (Paganetti 2012). The complexities of tissue geome-
tries and densities thus affect the accuracy of the analytical dose calculation.
This effect as a function of geometric complexity and proton energy was stud-
ied for example by (Sawakuchi et al. 2008), who reported an uncertainty of
the falloffs of the dose profiles in the order of ∼2 mm for a 220 MeV proton
beam. Nowadays, Monte Carlo (MC, cf. section 4.1) dose simulations are used
within most advanced TPSs to overcome this effect. Using MC dose engines,
a huge amount of incident particles (e.g. 105 particles per PB) is simulated
in the heterogeneous tissue geometry and composition, passing through ran-
dom path sampling and interaction from probability distributions calculated
by the system, thereby typically achieving a more accurate dose calculation. A
comparison between analytical and MC dose distributions in the same patient
anatomy is shown in figure 2.7.
Treatment delivery
Usually delivery of the therapeutic treatment is fractionated over several weeks
and thus performed at different time points, where the actual patient anatomy
can be different from the planning CT (pCT). This may be due to not only
potential anatomical changes caused by, e.g. weight loss, tumor shrinkage or
tissue swelling, but also alignment issues due to e.g. positioning uncertainties in
each treatment session. Additionally, patient anatomical locations can change
within the treatment delivery due to e.g. breathing and heartbeats. Both
inter- and intrafractional changes lead to unwanted proton range uncertainties.
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Figure 2.7: The dose calculated using a simple analytical dose engine of a research TPS
CERR (Deasy et al. 2003, Resch et al. 2017) (cf. section 4.1) is shown on the left (note that
the used CERR system does not implement pencil beam splitting, thus showing inferior
performance than commercial TPSs), while the MC dose for the same PB is shown in the
middle (on the planning CT, pCT). The right figure shows the MC dose calculation for
the same PB in the case of a substantial anatomical change (on a different CT).
This effect is shown in figure 2.7 for an example of inter-fractional anatomical
change.
Different approaches are applied to mitigate the planning uncertainties with robust treat-
ment planning algorithm (Inaniwa et al. 2011) or improved image guidance to capture daily
anatomy using e.g. cone beam CT (CBCT) (Venkatesh & Elluru 2017) or improvement of
the stopping power estimation using e.g. dual energy CT (DECT) (Goo & Goo 2017) and
proton CT (pCT)(Testa et al. 2013).
This work focuses on the in-vivo proton range verification using prompt gamma imaging.
2.3.2 Approaches for in-vivo range verification
To overcome the issue of proton range uncertainties, extensive research is ongoing to de-
velop techniques that can enable an in-vivo monitoring of the actual proton beam range,
ideally during delivery. This ambitious goal can be achieved by detecting the thermoacous-
tic signals accompanying proton irradiation of tissue (for pulsed beams only) or secondary
particles, particularly energetic photons, generated in nuclear reactions, i.e. ionoacoustics,
positron emission tomography (PET) and prompt gamma (PG) imaging. These tech-
niques, at a different level of maturity and clinical translation, are briefly described in the
following.
Ionoacoustics
Energy lost by pulsed ion beams penetrating a medium can cause a localized
heating and a thermal expansion, generating detectable thermoacoustic emis-
sions. By detecting the weak pressure waves (ionoacoustic signal), especially
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Figure 2.8: Schematic setup of ionoacoustics detection of pulsed proton beams in a water
tank
using time-of-flight (TOF) measurements in combination with the knowledge
of speed of sound in the traversed medium, the Bragg peak of a pulsed proton
beam can be monitored in vivo (Parodi & Assmann 2015). A schematic setup
of ionoacoustics is shown in figure 2.8. It was as early as 1979 that the fea-
sibility of ionoacoustics was first investigated for beam diagnostics by (Sulak
et al. 1979). In 1995, the first clinical investigation was conducted by (Hayakawa
& Tsujii 1995) during the pulsed proton treatment of a liver cancer patient.
However, due to the lack of tailored instrumentation and suboptimal passive
proton delivery systems, the complexity of the ionoacoustic signals limited the
performance of this proof-of-principle clinical investigation. The ionoacoustic
technique reveals more potential nowadays because of the more favorable active
beam delivery, along with improvements of ultrasound transducer technology
as well as the commercial establishment of intrinsically pulsed proton acceler-
ators (synchrocyclotrons).
The dose deposition profile can also be reconstructed by detecting and mathe-
matically inverting the acoustic waves produced upon the energy loss of protons
in water/tissue (Kellnberger et al. 2016). According to (Assmann et al. 2015),
the Bragg peak position and the full width at half maximum (FWHM) of its
Bragg peak width predicted by a MC simulation platform based on the code
Geant4 (Geometry and Tracking 4, (Agostinelli et al. 2003)) were found in
sub-millimeter agreement with 1D ionoacoustic measurements in water at a re-
search 20 MeV pulsed proton beam. In the same homogeneous target (water),
the accuracy of ionoacoustics-based proton range verification was found to be
better better than 1.5 mm for pulsed delivery of 50 MeV protons, although in
the case of high dose delivery (average of 1024 pulses, each delivering 2 Gy) for
the considered experimental setup and detector technology (Patch et al. 2016).
The feasibility of this technique was also proven more recently using a synchro-
cyclotron at clinical energies (Lehrack et al. 2017), where ionoacoustic range
measurements in water showed sub-millimeter range accuracy and precision at
a Bragg peak dose of about 10 Gy for 220 MeV initial proton beam energy.
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Similar results were also reported for an artificially pulsed clinical cyclotron in
(Jones et al. 2015). However, the power of this technique is still challenged
by several issues, e.g. the requirement of dedicated instrumentation of high
sensitivity and large bandwidth, the knowledge of the acoustic tissue proper-
ties and the difficult exploitation of complex signals caused by tissue hetero-
geneities. Nevertheless, the promising simulation studies in clinical scenarios
that have been conducted recently still motivate the ongoing developments
of this cost-effective technique for anatomical locations of easy acoustic access
(e.g., prostate, breast), ideally in combination with diagnostic ultrasound imag-
ing for co-registration of the Bragg peak to the underlying anatomy [Assmann
et al., 2015, Hickling et al., 2018, Jones et al., 2018, Patch et al., 2018].
Positron emission tomography
Figure 2.9: Schematic setups of PET and PG based proton range verification are shown
on the top and bottom, respectively. Various types of PG systems are discussed in the
following chapter. The exemplary PET imaging is from the work of (Remmele et al. 2011).
Using PET imaging for range verification of ion beam therapy was first pro-
posed by (Maccabee et al. 1969). PET-based proton dose monitoring was then
investigated by different groups during the 90s (Litzenberg et al. 1993, Vynckier
et al. 1993, Paans & Schippers 1993, Oelfke et al. 1996, Litzenberg et al. 1999),
and regained interest since the late 2000s.
In proton therapy, positron emitters are generated along the beam path through
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nuclear fragmentation reactions, leaving a footprint of radiotracers that decay
via positron emission (Zhu & Fakhri 2013). Two anti-parallel coincidence gam-
mas of 511 keV are generated when the emitted positron travels a small distance
and then annihilates with an electron in the medium. The falloff of the PET
signal is well before the Bragg peak, around 4-6 mm (Parodi & Enghardt 2000).
The rapid falloff of the dose delivery, i.e. proton range, can thus be inferred by
the distribution of the positrons emission monitored by detecting those gammas
using a PET detector (Parodi 2012). A schematic set up of a PET system is
shown on the top of figure 2.9.
The spatial distribution and integral yield of several species of radionuclides
(15O, 11C, 30P, 38K, etc) for clinically planned proton treatments for head and
neck and paraspinal tumors was calculated using MC simulation by (Parodi
et al. 2007a, Parodi et al. 2007b). The most important radionuclides produced
in the case of soft tissues are 11C, 13N and 15O. The 15O is the dominant radionu-
clide produced during irradiation due to the high oxygen density, but rapidly
decays due to the half-life of only ∼2 min, while 11C contributes more to the
activity measured after irradiation, because of its longer half live of 20.3 mins
(Valverde et al. 2018). Hence, the PET signal depends on the timing of the
data acquisition and underlying contributing isotopes during or after irradia-
tion, when using PET scanners located inside or outside the treatment room.
However, due to the different physical processes involved, the dose distribution
cannot be directly correlated with the positron activity. Moreover, depending
on the time elapsed between irradiation and imaging, the PET-dose correlation
can be additionally challenged by the low signal-to-noise ratio and distortions
caused by physiological processes, so called washout.
To perform the PET-based proton range verification, the PET measurement
estimation is firstly created by either using analytical methods (Parodi &
Bortfeld 2006, Miyatake et al. 2011) or MC simulation, which is the most
accurate method and was firstly proposed and applied on 9 patients in a clin-
ical study using a remote PET/CT scanner in (Parodi et al. 2007b). To this
end, the simulated proton fluence spectrum, according to the detailed MC sim-
ulations of the TP, was convolved with the energy dependent cross section for
the main reaction channels and then scaled with the target nuclei densities de-
duced from the patient CT. Corrections for biological washout and radioactive
decay were applied taking into account the time of irradiation and offline data
acquisition. The simulated PET image was finally obtained using a convolu-
tion kernel to model the resolution of the scanner, and then compared to the
measured image, reconstructed by the commercial scanner, to estimate whether
the dose was delivered as planned. Range verification accuracy of 1-2 mm was
achieved in head and neck cancer patients in the case of good immobilization
and registration between treatment and imaging CT as well as reduced washout
in bony structures (Parodi et al. 2007b). In the cases of other anatomical sites,
an accuracy of only 3-5 mm was found, indicating a lack of millimeter range
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accuracy for every tumour indication (Knopf & Lomax 2013). Recently, a ded-
icated in-beam dual head PET scanner has been developed to overcome the
limitations of offline PET imaging and to detect the activity during irradiation
(Ferrero et al. 2018), with a first clinical evaluation ongoing.
Prompt gamma imaging
Nuclear excitations and related PG emissions due to inelastic interactions of
incident protons and nuclei in the beam path occur until the energy of primary
protons decrease below the reaction threshold, which is typically a few millime-
ters before the Bragg peak, resulting in a falloff close to the Bragg peak in the
case of PG(Knopf & Lomax 2013) (cf. figure 2.10). This is similar to what de-
scribed for PET, but the energy threshold is typically lower. The energetic PGs
are emitted by the de-excitation of the excited nuclei to the lower energy states
(cf. table 2.1). Discrete gamma emissions can be extracted from the standard
measurements (Verburg et al. 2012) when the cross sections of the transitions
of the quantized energy states of excited nuclei are high enough. This process
strongly depends on the energy of the incident protons and the tissue compo-
sition of the target. The gamma lines resulting from the interaction between
protons and the most abundant elements in human tissue, i.e. 12C, 16O, and
14N, are shown in table 2.1 (Kozlovsky et al. 2002, Verburg et al. 2012). A
schematic setup of a PG system is shown on the bottom of figure 2.9, and more
details of proposed detection schemes will be given in chapter 3.
For 12C, the 4.44 MeV line is the dominant contribution. For levels above
the 4.44 MeV line, most of the 12C decays through alpha emission (Ajzenberg-
Selove 1990). For 16O, most of the gamma emissions are contributed by the lines
at 6.13, 6.92 and 7.12 MeV in the case of low energy protons (Tilley et al. 1993),
while the contribution of the 16O(p,x)12C∗ reaction channel increases due to the
4.44 MeV PGs from the residual 12C∗. Due to the typically lower abundance
in tissues, compared to 12C and 16O, 14N contributes less to PG emission.
Compared to PET based proton range verification, PG has higher production
rates (especially in the case of a therapeutic dose rate of 2Gy/min) (Moteabbed
et al. 2011). Moreover, PG needs shorter time for detection (within a few
nanoseconds after the nuclear interaction induced by the irradiation), hence al-
lowing good on-line monitoring if detectors of sufficient detection efficiency are
available. The PG signal is also better correlated with the primary range be-
cause the cross sections for PG production have typically lower energy thresh-
olds than for positron emitter yields (Moteabbed et al. 2011). Finally, the
positron emitted in the β+-decay has a certain range in tissue before annihilat-
ing with an electron, thus intrinsically limiting the achievable spatial resolution
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Target elements Reaction channel Eγ (MeV) Transition Mean life (s)
12C 12C(p,x)11C∗ 2.00 1
2
−
2.00 → 3
2
−
g.s. 1.0×10−14
12C(p,p’)12C∗ 4.44 2+ → 4.44 0+ g.s. 6.1×10−14
16O 16O(p,p’)16C∗ 2.74 2− 8.87 → 3− 6.13 1.8×10−13
6.13 3− 6.13 → 0+ g.s. 2.7×10−11
6.92 2+ 6.92 → 0+ g.s. 6.8×10−14
7.12 1− 7.12 → 0+ g.s. 1.2×10−19
16O(p,x)12C∗ 4.44 2+ → 4.44 0+ g.s. 6.1×10−14
16O(p,x)15N∗ 5.27 5
2
+
5.27 → 1
2
−
g.s. 2.6×10−12
14N 14N(p,p’)14N∗ 1.64 1+ 3.95 → 0+ 2.31 6.9×10−15
2.31 0+ 2.31 → 1+ g.s. 6.9×10−15
5.11 2− 5.11 → 1+ g.s. 6.3×10−12
Table 2.1: Reaction channels of relevant PG emissions in proton therapy (g.s. ground
state) (Kozlovsky et al. 2002, Verburg et al. 2012).
of PET imaging.
Collimated detection of PG was firstly explored in an experiment by (Min
et al. 2006), in which the distance between the Bragg peak and the maximum
of the PG distribution was within 1-2 mm in the case of protons with 100 MeV
initial energy stopped in water. Due to the deeper penetration depth and higher
neutron background, this distance increased in the cases of higher energy pro-
tons (150 and 200 MeV). Different studies, both experimental and simulation,
have been conducted to further explore the feasibility of PG-based proton range
verification in the successive years (Polf et al. 2009a, Polf et al. 2009b, Kang
& Kim 2009, Frandes et al. 2010, Richard et al. 2011, Draeger et al. 2018).
The first clinical PG imaging was conducted in a study of passively scattered
proton therapy of a head and neck cancer patient at OncoRay in 2016, Dres-
den, Germany and a global inter-fractional range shift in the order of 2.0 mm
was detected (Richter et al. 2016). In 2017, the first clinical spot-by-spot PG
imaging for active scanning was conducted for a relatively homogeneous case
of a brain tumor by (Xie et al. 2017), demonstrating that a retrieval precision
of 2 mm can be achieved. Since then, this is a very active field of research, as
reviewed in the next chapter.
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Figure 2.10: The distributions of the MC calculated dose and corresponding PG emission
are shown on the left and right, respectively.
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Chapter 3
PG range monitoring
3.1 PG-based proton range verification systems
PG-based proton range verification cannot rely on standard nuclear medicine instrumen-
tation tailored to low-energy (typically 140 keV) single photon detection, but requires
dedicated cameras to overcome the challenges of a broad- and high-energy distribution in
the multi-MeV range, high instantaneous count rate and compatibility constraints with
patient irradiation. Several types of PG devices have been proposed over the last decade
to retrieve directional information of the PG emission, correlated with the beam range,
exploiting either mechanical or electronic collimation (Krimmer et al. 2018). Regardless of
the chosen detection scheme, a considerable background resulting from the simultaneously
created neutrons may limit the signal-to-noise ratio of PG imaging. This is caused by
direct interactions of the neutrons in the detectors and/or from photons produced by the
neutrons within the collimators and/or other structures including the patient surrounding
the detectors. Neutrons directional and spatial correlation with the proton range is typ-
ically lost due to neutron scattering in the patient and surrounding. Thus, the effect of
the neutrons on the PG signal can only be detrimental and needs to be suppressed. To
this end, (Biegun et al. 2012) proposed to use time of flight (TOF) detection to reject neu-
tron background. Their MC simulation showed that using a shifting time window with a
width of TOF of 1.0 ns can significantly reduce the neutron background (more than 99%),
especially in the case of proton beams with a microstructure that is typical of cyclotron
accelerators. In addition to the timing properties of the PG, which can also be exploited
to retrieve proton range information or as a global monitor of the applied treatment, also
their energy is a characteristic feature specific to the involved nuclear de-excitation process.
The idea to exploit the energy information of PG was firstly proposed and investigated by
(Polf et al. 2009a). In their pioneering simulation and experimental studies, it was shown
that it is possible to distinguish the characteristic PG emission lines from the major ele-
mental constituent atoms (C, O, Ca) during proton dose delivery. Hence, recent systems
aimed to combine directional detection with spectroscopic PG information to increase the
robustness of the proton range verification approach, additionally offering the possibility
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to recover the main carbon and oxygen tissue composition in the region of interest imaged
by the system. A summary of all these detection technologies is given in the following.
3.1.1 PG detection prototypes
Collimated systems
Pinhole/knife edge cameras
The first feasibility study of PG range verification has been performed by (Min et al. 2006),
using a single CsI(Tl) scintillation detector behind a collimator with a parallel slit geom-
etry. Measurements have been performed irradiating a water target with mono-energetic
proton beams in the 100-200 MeV energy range, and a dedicated collimator (at 90◦ from
beam direction) has been designed to moderate and capture fast neutrons as well as to
prevent unwanted prompt gamma rays not perpendicular to be the beam direction to reach
the scintillation detector. The PG profile has been obtained via a scan of the target in
front of the collimator detector arrangement (sensitive to the collimator alignment to the
detector). A promising correlation of the distal falloff region of the PG distribution with
the additionally measured depth dose distribution has been observed (Min et al. 2006).
Another promising experiment using a CsI(Tl) scintillation detector behind a pinhole aper-
ture for high energy PG detection was performed by (Kim 2009). The idea is to use the same
principle as an optical pinhole camera for high energy PG detection. Similar concepts of col-
limated systems were then investigated and optimized in extensive Monte Carlo simulation
studies by different groups, e.g. (Bom et al. 2011). It was in 2012 that the first prototype
of a knife-edge camera, consisting of one lutetium-yttrium oxyorthosilicate (LYSO) crystal
behind a slit collimator (Peloso et al. 2010, Busca et al. 2010), was built by the company
IBA in collaboration with Politecnico di Milano (Smeets et al. 2012). This design is based
on the HiCam system, a compact Anger gamma camera developed in the framework of the
HiCam (high resolution camera) project (Fiorini et al. 2008, Peloso et al. 2010), which can
achieve a very good intrinsic resolution of 0.8 mm FWHM when imaging 140 keV gamma
rays from 99Tc (Smeets et al. 2012). The initial HiCam system was designed for nuclear
medicine applications where both high resolution and compactness are required, such as
diagnosis of brain tumours, breast and thyroid cancer as well as small rodents imaging for
the evaluation of pharmaceutical distribution or functional effects resulting from medical
treatments (Busca et al. 2010). The second generation of this prototype was established
by using LYSO scintillator slabs read out by silicon photomultipliers in order to improve
the system in terms of counting statistics and photon-detection efficiency at the higher
energies of interest for PG monitoring. The retrieved PG measurement is sensitive to the
position of the camera, which means that the alignment should be performed with respect
to the patient along the beam direction instead of the beam isocenter.
Although originally designed for the PB scanning delivery technique (see chapter 2), the
first clinical implementation of the IBA knife-edge camera was conducted in 2016 for pas-
sively scattered proton therapy of a head and neck cancer patient at OncoRay in Dresden,
Germany. A global inter-fractional range shift in the order of 2.0 mm was detected in the
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Figure 3.1: The left panel shows the concept of the slit camera: a slit collimation gives
a 1D projection of PG emission along the beam path on a scintillation detector. The
configuration of this system is shown on the right panel (Perali et al. 2014).
monitored 7 fractions, and was found in good agreement with the information deduced
from dose recalculations on in-room control CTs (Richter et al. 2016). The second clinical
implementation was performed by (Xie et al. 2017) in PB scanning proton therapy for a
brain cancer patient at the University of Pennsylvania. The detected average range shift
was within 1.0-2.0 mm, which is below the fixed distal margin of 5.0 mm applied clinically.
The retrieval precision was reported to be affected by the amount of delivered protons,
and a proton statistics (i.e. number of protons) of 2 × 108 was postulated to be needed
for a reliable monitoring, which could be achieved by aggregating the collected signal from
nearby PBs in the conventional TP (referred to as spot aggregation, explained more in
detail in chapter 5).
A schematic setup is shown in figure 3.1. In this thesis work, the detection of PG by a slit
camera is simulated using the Matlab-based toolkit REGistration Graphical User Interface
(REGGUI) developed by the company IBA (Janssens et al. 2011). Relevant details will be
given in chapter 4.
Multi-slit camera
This approach is an evolution of the single slit camera, i.e. using multiple detectors behind
parallel slit collimators placed perpendicular to the proton beam direction (schematic setup
shown in figure 3.2). PGs emitted from the target would pass through the corresponding
collimator slit (sensitive to the position of the detector). The detectors are typically able
to resolve energy and thus the resulting counts in a selected energy window (e.g. 1.1-10
MeV in the work of (Krimmer et al. 2015)) in the detector are registered. The measured
PG distribution can be correlated to the distal falloff of the dose and with the knowledge
of the 2D position of the beam entrance in pencil beam scanning delivery (from the TP or
a fast detector in the beam), the 1D longitudinal PG information is complemented (Min
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Figure 3.2: Schematic setup of a multi-slit camera system for PG measurement (Min
et al. 2012).
et al. 2012, Krimmer et al. 2015). Measurements of PG generation as a function of proton
penetration depth in the target have been conducted using crystal scintillators by (Pinto
et al. 2015) and using semiconductor detectors by (Kelleter et al. 2017). By using these
multi-slit camera systems, the field of view can be enlarged with respect to the previous
single-slit solutions to encompass the complete beam path. Compared to other detection
systems described in the next section, the multi-slit camera has good spatial resolution
and does not rely on a reconstruction algorithm, although the signals could be blurred by
inter-detector scattering (Pinto et al. 2014). According to the work of (Park et al. 2019),
the signal quality of this camera prototype can be further improved by (1) using more
detector modules, (2) increasing the size of the scintillator, (3) decreasing the length of the
slit of the multi slit collimator.
Compton camera
A Compton camera (CC) system consists of one or multiple scatterer detectors, typically
thin enough to enable only one scattering event per layer, usually followed by a thicker ab-
sorber detector of high atomic number. Incident gammas thus primarily undergo Compton
interaction in the scatterer detector and are ideally fully absorbed with the photoelectric
effect in the absorber detector. The kinematics of Compton scattering is used by this sys-
tem to construct a source imaging without the use of collimators or masks (Phillips 1995).
The direction of the incident gamma is restricted to the surface of a cone with an aperture
equal to the Compton scattering angle. This information is used for the 3D reconstruction
of the PG emission.
Compton telescopes were first built in the 1970s for astronomical observations. In 1974
the first CC for medical imaging was proposed by (Todd et al. 1974) and then investigated
by (Everett et al. 1977) using a simplified detector prototype with two segmented semicon-
ductor layers. In the last decade, Compton cameras have attracted much attention for in
vivo proton range verification. The idea is to exploit Compton kinematics to restrict the
direction of the incident photon to a cone based on the energy deposition and interaction
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Figure 3.3: Schematic configurations of CC detectors. The left and middle panel shows
a classic CC consisting of two and multiple detectors, respectively. On the right is the
electron tracking configuration consisting of several thin layers able to register the path of
the recoil electron. Ideally, the Compton scattered gamma interacts in a thicker detector
component for full absorption, and the initial direction may be completely determined (δ
and θ represent the total scattering angle and the photon scattering angle, respectively).
points in segmented or position sensitive monolithic detectors. Thus, the vertex of the pho-
ton generation is obtained via the superposition of multiple cones. This allows Compton
cameras to create 3D PG information. Besides, in the relevant PG energy range of several
MeV, Compton scattering is the dominant process and Compton cameras are well adapted
in this case for the purpose of prompt gamma-ray detection (Krimmer et al. 2018).
The simplest Compton camera uses two detectors as shown in figure 3.3 left. This kind
of Compton camera requires a total absorption of the scattered photon in the absorber
for correct kinematics reconstruction, since the energy of the produced PG is a priori not
known. However, this full absorption cannot always be guaranteed at the typical high
energies of PG produced in proton therapy. Algorithms have been developed to use the
elemental composition of the target to constrain the energy of the PG to a few discrete lines
(Xu & He 2007, Draeger et al. 2016). An alternative (figure 3.3 middle) is to use two (or
more) scatterers, so the kinematics of the incident PG can be completely determined and
full absorption is no longer needed, although the efficiency is reduced by at least an order
of magnitude (Roellinghoff et al. 2014). In contrast, the usage of multiple thin scatterer
detectors as shown in the right panel of figure 3.3 can additionally enable the measurement
of the recoil electron direction. This provides information about the total scatter angle
that restricts the origin of the incident PG to an arc segment, again not requiring full
absorption. Despite the good correlation shown for the measured PGs with the proton
range, this approach is limited by the low efficiency of multiple interactions (Kurosawa
et al. 2012).
Different CC prototypes have been developed using different detector technologies based
on scintillators or solid state materials, e.g. the Polaris-J CC developed by H3D Inc.
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for the group of Prof. Polf at University of Maryland (McCleskey et al. 2015, Polf &
Parodi 2015, Draeger et al. 2018) and the MACACO CC developed by (Llosa et al. 2016)
at instituto de Fisica Corpuscular, Valencia, Spain and CERN, Meyrin, Switzerland. This
promising field is still in progress to allow the full deployment of CC into the clinic by e.g.
improving count rate (Draeger et al. 2018) and reducing the cost (Krimmer et al. 2018).
Integrated yields counting systems
Prompt gamma timing (PGT)
PGs are emitted throughout the penetration process of protons in matter, as long as the
energy is above the threshold for nuclear interaction. The proton transit time depends on
the proton range (1-2ns for a range of 5-20 cm in the patient’s body) and is reflected in the
width of PG TOF distribution. The idea of monitoring proton range by measuring only the
uncollimated PG TOF with respect to a given start signal (corresponding to the time the
protons enter the target) was first proposed and investigated by (Golnik et al. 2014) using
150 MeV protons impinging on a graphite target. A fast scintillator detector, GAGG:CE
(cerium-doped Gd3Al2Ga3O12) scintillator (Kamada et al. 2012) coupled onto a Photonics
XP2972 photo multiplier tube (PMT), was used in this work as primary detector. The
feasibility of this method was investigated in terms of the effect of changes in e.g. the
target position, target thickness, incident proton energy and target components (air and
bone) on the TOF distribution. The schematic configuration of the PGT method is shown
in figure 3.4. The setup of the mentioned study is shown in figure 3.5.
In the case of high statistics, i.e. 1010 primary protons, range differences of 2.0 mm were
Figure 3.4: Schematic configuration of PGT. A PG is emitted along the beam track at xp.
The time tp has elapsed since the corresponding particle entered the target. The emission
of the PG is assumed to be instantaneous. The tγTOF is the time for the PG reach the
detector, which is largely dominated by the transit time. A detection system is measuring
the time difference between the time of the particle entering the target and the arrival
time of the PG at the detector. The measured distribution is denoted as PGT spectrum
(Golnik et al. 2014).
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Figure 3.5: 150 MeV proton beams are delivered in a graphite target (density: 1.7 g/cm3)
at three different positions A, B and C, as shown on the left. The corresponding measured
PG timing distributions, detected in this case by a GAGG detector, are shown on the right
(Golnik et al. 2014).
resolved in homogeneous phantoms. The minimum range shift detected is less than 5.0
mm in the case of reduced statistics (Hueso-Gonzalez et al. 2015). The possible clinical im-
plementation of the PGT method has been investigated at the University Proton Therapy
Dresden using a pencil beam scanning plan (Werner et al. 2019). The proton range changes
caused by material variation could be identified from the corresponding PGT spectra. An
assignment of the PGT data to the individual PB allowed a spot-wise analysis of the vari-
ation of the PGT distribution mean and width, corresponding to range shifts produced by
different air cavities (Werner et al. 2019). However, an excellent time resolution less than
1 ns is needed. This value might already be degraded by the time structure of the beam,
especially with the accelerators of synchrocyclotron type (Krimmer et al. 2017).
Prompt gamma peak integral (PGPI)
To detect gross deviations in treatment delivery of proton therapy, (Krimmer et al. 2017)
investigated the peak integrals of the distribution of uncollimated PG TOF at Centre
Antonie Lacassagne in Nice, France. This approach enables to use an affordable and in-
dependent monitoring system to retrieve the TOF information, providing the possibility
to discriminate the PGs generated in the beam line from those originated in the target.
The combination of signals from multiple detectors placed around a target can be used to
detect a misplacement of the target or provide a precise number of the registered PG that
is independent of the target position (Krimmer et al. 2017).
Experiments showed that the PG peak integrals (PGPI) are sensitive to variations in the
registered PG ray counts. A range shift of 3.0 mm in PMMA in the case of 108 protons can
be detected by using the detectors covering a solid angle of 25 msr (Krimmer et al. 2017).
A schematic setup is shown in figure 3.6.
Prompt gamma spectroscopy (PGS)
The prompt gamma spectroscopy (PGS) technique verifies the proton range by matching
the energy- and time resolved PG measurements with models based on experimentally de-
termined reaction cross sections (Verburg et al. 2013). The discrete gamma lines, attributed
to specific nuclear level transitions, are identified in this approach, providing several ben-
efits to improve the accuracy and sensitivity of range verification with a collimated PG
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Figure 3.6: Configuration for the measurements of PGPI with cerium doped LaBr3 and
BaF2 scintillation detectors (left) and the TOF spectra corresponding to different positions
(degrees of rotation) of the modulator wheel (right). After subtracting the background (red
line), the signals (blue) corresponding to the PG emission from the target are integrated
within the limits (vertical dashed lines) (Krimmer et al. 2017).
detection system. First, each of these discrete PG emissions has a unique correlation to
the proton energy and the cross sections of nuclear reaction that can be used in the proton
range verification. Second, it provides the possibility to estimate the elemental concentra-
tions of the target, making the range verification more robust if the proton beam stops in
a tissue with an uncertain composition (Verburg et al. 2013).
The feasibility of this method has been demonstrated by (Verburg 2015) for passively
scattered proton beams and by (Hueso-Gonzalez et al. 2018) for pencil beam scanning. In
particular, the results of the latter experiment (setup shown in figure 3.7) demonstrate for
the first time that a proton range verification precision of 1 mm is achieved in phantoms
under clinically realistic conditions. The detection scheme is still mechanical collimated
but with additional good energy resolution (provided by LaBr3) of the detector and TOF
for background suppression Hence, a new full-scale clinical prototype detection system
based on PG spectroscopy has been developed and will be deployed for the clinical study
with patients soon, see figure 3.8.
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Figure 3.7: Schematic of the experimental setup of the PGS system demonstrated in
(Hueso-Gonzalez et al. 2018). Protons (red arrow) irradiated a water phantom with dif-
ferent settings (a. no range error; b. solid water block covering half of the field; c. 2.2
and 5.2 mm water equivalent range shifters covering half of the field; d. 5mm thick slab
of inner or SB3 cortical bone inserted in the middle of the field). The PG are collimated
(gray) and measured with scintillation detectors of excellent energy and timing resolution
(green).
3.2 Dependence of PG signal with counting statistics
The precision of the retrieved range from the PG signal is sensitive to the Poisson noise in
the detected profiles. Spot-by-spot PG simulation using the IBA knife-edge system based
on LYSO scintillating crystals conducted by (Xie et al. 2017) pointed out that a shift re-
trieval precision of 2 mm can be achieved when the number of protons is more than 2×108
(figure 3.9). The range resolving ability of a CC based on 3 layers of semiconductor detec-
tors was investigated by (Draeger et al. 2018) during the irradiation of a tissue-equivalent
plastic phantom with proton PBs for clinical doses delivered at clinical dose rates. The
result showed that 3D images of PG emission can be produced with the delivery of as few
as 1× 108 protons and shifts in the proton beam ranges as small as 3 mm can be detected.
As expected, profiles generated using 1e8 protons are much noisier than those generated
using a higher statistics of 6.29× 108 protons (Draeger et al. 2018) (figure 3.10 and 3.11).
In this thesis work, Geant4 simulations are employed to explore the correlation between
the statistics of incident protons and the precision of PG collected by a phase space detec-
tor surrounding the target, which records all PG hit events in terms of position, energy,
momentum and TOF. Relevant details of the code and results will be shown in section 4.1
and 5.1, respectively.
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Figure 3.8: Left: 3D model of the clinical PGS prototype system. Right: photo of the
system in the gantry treatment room. The red arrow shows the proton beam incidence
direction. (Hueso-Gonzalez et al. 2018)
3.3 Influence of tissue heterogeneities on PG-based
proton range verification
In addition to counting statistics, the accuracy of the PG based proton range verification
can be affected by tissue heterogeneities, which may significantly alter the shape of PG
distributions and change the correlation between the proton range and the PG depth
profile.
This was experimentally investigated by (Priegnitz et al. 2015) using the IBA knife-edge
slit camera (see section 3.2.1) during proton irradiation for tissue-equivalent targets. The
PG range monitoring fails when the PG distal falloff is placed near pronounced density
gradients, i.e. the beam stops in close vicinity to air cavities or low density lung tissue (see
figure 3.12) (Priegnitz et al. 2015).
Similar effects were also reported in the MC study of (Schmid et al. 2015). The Bragg
peaks may be distorted when there are large transversal tissue heterogeneities close to the
end of the proton range and the shift calculation for PG profiles might be unreliable due
the the changes of the falloff pattern caused by the complexity of the inhomogeneous tissue
(see figure 3.13 and 3.14). In this case, the correlation between the falloffs of PG and dose
profiles would be poor.
In this thesis work, the correlation between the falloffs of dose and PG as well as the
effect of tissue heterogeneities on the dose delivery are investigated and quantified, as
explicitly addressed in chapter 5 and 6.
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Figure 3.9: (Left) Precision of BP shift retrieval according to the evaluation presented in
(Xie et al. 2017) for the IBA knife-edge camera. Top: number of protons per PB spot.
Middle: expected and observed shift retrieval precision. Bottom: fraction of spots achieving
a shift retrieval precision better than 2 mm as a function of lateral spatial resolution,
defined as the sum in quadrature of the beam sigma and the sigma of the aggregation
kernel explained in section 5.2. (Right) Example of the comparison between the measured
and simulated PG profiles for an individual PB spot (top), for the aggregated spots (with
an aggregation kernel of 7 mm sigma, middle) and for the entire energy layer including all
PB spots (bottom) (Xie et al. 2017).
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Figure 3.10: PG images obtained with the Polaris CC for the delivery of 6.29× 108 (left)
and 1 × 108 (right) protons for the full range of the irradiated 120 MeV PB (top), 3 mm
range shifted PBs (middle), and 5 mm range shifted PBs (bottom), each normalized to the
respective maximum value. The dashed lines represent the position of the distal 90% of
the full range pencil beam (Draeger et al. 2018). The corresponding profiles are shown in
figure 3.11
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Figure 3.11: PG emission profiles extracted from the CC images of figure 3.10 for the
delivery of 6.29× 108 (a) and 1× 108 (b) protons for the full range and for the range shifts
of 3 mm and 5 mm compared to the central axis depth dose profile for the full range 120
MeV PB. (c) and (d) show a close up of the final 5 cm of the beam penetration depth to
highlight the shift in the PG profile as the beam range was shifted (Draeger et al. 2018).
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Figure 3.12: Simulation of the expected PG detection (dash-dotted) and the PG emission
with energies between 3-8 MeV (solid colored lines) for the irradiation of an anthropomor-
phic head target with (green)/without (red) air cavity. The Hounsfield units (HU) of the
irradiated target and the range of the protons are given by the gray solid and dotted lines,
respectively. Left: 137.5 MeV protons with range 5 mm beyond the air cavity. Right: 144
MeV protons with range 5 mm beyond the air cavity. In the right figure, although the
anatomy has changed, there is almost no PG shift detected as the algorithm calculates the
shift by minimizing the area between the falloffs of both PG profiles (dash-dot) (Priegnitz
et al. 2015).
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Figure 3.13: Depth dose profiles and PG emissions along with the corresponding PG falloff
fittings of 4 proton PBs simulated in a clinical CT image of a prostate patient. In (B), the
dose falloff is not as sharp as that in (A), resulting in a gradual PG falloff. (C) and (D)
show profiles with large variation compared to a typical steep pristine Bragg peak in (A),
due to distal tissue heterogeneities (Schmid et al. 2015).
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Figure 3.14: The shift of the dose and PG laterally integrated profiles of a proton PB
delivered on CTs of a prostate patient at different time points are shown on the left and
right, respectively. The actual dose shift cannot be correctly estimated using the PG
shift. In this case, using the PG signal as a surrogate of the beam range could lead a
misevaluation of the dose shift (Schmid et al. 2015).
Chapter 4
Computational Tools used
Monte Carlo simulations are used in this work to calculate the dose and PG distributions
based on the patient CT. The first part of this chapter introduces the Monte Carlo treat-
ment planning system for proton therapy along with other computational platforms used in
this research, and how the dose and PG signals are scored. The second part of this chapter
introduces the basic knowledge of machine learning, which is used for pattern recognition
of the PG falloff used in the signal analysis.
4.1 Computational platforms for treatment planning
and dose/PG distributions
4.1.1 Patient data
In the first part of this work, the planning X-ray CT scans of three anonymized head and
neck (called H&N in the following) cancer patients (H&N1, H&N2 and H&N3) are used.
The second part of this work focuses on the performance of the developed methods on
different CTs of the same patient taken at different points in time. The CTs of one H&N
and one prostate cancer patient (H&N4 and PROST1) at three different time points are
used. The planning CT is called CT1 while the subsequent CTs are called CT2 and CT3,
respectively.
For the third part of this work, the proposed approach is tested taking into account a real-
istic detector response, in combination with an indicator based on the PG camera position.
The same CTs as in the second part of this work are used.
All the CTs refer to anonymized data of patients undergoing photon therapy at the Univer-
sity Hospital of the Ludwig-Maximilians-Universität München. The CT data were acquired
at a Toshiba Aquilion LB scanner (Toshiba Medical Systems, the Netherlands) and the
corresponding images were reconstructed on a 1.074× 1.074× 3 mm3 grid.
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4.1.2 Monte Carlo simulations
Monte Carlo simulations are based on algorithms that repeat random samplings so that ex-
pected values of the variables of interest are obtained by taking the mean of those indepen-
dent samples. This method is based on the law of large numbers. The use of MC techniques
in the field of medical physics has been increasing since the 1970s (Andreo 1991, Yang &
Bednarz 2013, Andreo & Benmakhlouf 2017). Different MC tools are used for MC simula-
tions in medical physics, e.g. PENELOPE (Baro et al. 1995, Salvat & Sempau 1996, Sem-
pau et al. 2001), MCNP (Brown & Martin 2003), Geant4 (Agostinelli et al. 2003, Allison
et al. 2006, Allison et al. 2016) and FLUKA (B”ohlen et al. 2014) among others. MC
simulation of the three-dimensional (3D) dose deposition, PG emission and PG detection
in the first and second parts of this thesis is directly conducted using Geant4. For the
last part of this work, a fast MC engine for proton therapy named MCsquare (many-core
Monte Carlo) (Souris et al. 2016) is used for the 3D dose simulation and PENELOPE
precaculated data are used for the fast analytical calculation of PG emission and detection
(Sterpin et al. 2015).
Geant4 is a MC platform for the simulation of the passage of particles through mat-
ter. It is the successor of the Geant series of software toolkits developed by CERN us-
ing C++. Geant4 includes packages for handling geometry, tracking, detector response,
run management, visualization and user interface, allowing users to start immediately
on the more important aspects of the simulation while less time is needed to be spent
on the low level details. In this study, the Monte Carlo simulations were performed
with the version Geant4.10.02.p01 based on an extension of the DICOM example (Resch
et al. 2017). The transport and interactions of all primary and secondary particles, e.g.
protons, electrons, neutrons, gammas, nuclear fragments etc, are simulated using the pre-
defined QGSP BIC HP Geant4 physics list. This package uses the Geant4 Binary cascade
for primary protons with energies below 10 GeV, and can well describe the production
of secondary particles in hadronic interactions of proton and neutrons with nuclei. The
low-energy gamma and electron interaction processes including Doppler-broadening effects
are covered by the electromagnetic physics list (Geant4 2018). This package and physics
lists were chosen as they offers a good compromise between performance and speed. The
range cut of the secondary production threshold is set to 1 mm, corresponding to the CT
grid size. All settings are the same as in previous work on PG monitoring, e.g. (Schmid
et al. 2015, Lozano et al. 2016).
For calculations in the patient anatomy, the patient CTs are converted to tissue com-
position and mass density to construct a Geant4 geometry for the TP simulation using a
lookup table firstly proposed by (Schneider et al. 2000) (figure 4.1).
For scoring the quantities used in this thesis work in Geant4, the following approaches were
followed.
Dose and LETd scoring: The 3D dose and LETd of the simulated irradiation is scored
on the CT grid (Resch et al. 2017). At least 1 × 105 protons are needed for a reasonable
statistics in the spot-by-spot dose calculation, while the particle number for the TP simu-
lation is set to the total number of around 1×107, as recommended by (Resch et al. 2017).
4.1 Computational platforms for treatment planning and dose/PG
distributions 43
Figure 4.1: The lookup tables for the conversion of CT numbers to mass density (top) and
tissue composition (bottom), as proposed by (Schneider et al. 2000).
PG emission scoring: The 3D PG emission is scored on the CT grid for the PBs of
interest. Only PG with energy higher than 2.5 MeV are counted as gammas with lower
energy are not strongly correlated to the proton range (Kozlovsky et al. 2002, Verburg
et al. 2012, Schmid et al. 2015). As the PG production process is less frequent than the
energy deposition process, 5e5 protons were found to be needed to generate enough PG
emission counting.
Scoring of the phase space data of PG detection: To investigate the effect of statis-
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tics on the generic (i.e., not specific to a certain detector system) PG detection, a phase
space (phsp) scoring detector was set surrounding the patient CT in the Geant4 simula-
tion, and all PG reaching the detector were recorded in terms of their incident energy,
position, angle, and TOF. The energy threshold of a valid PG detection event is set to 2.5
MeV which is the same as that for PG emission. The threshold of the acceptance angle
is set to 4 degree to be consistent to the previous study of (Schmid et al. 2015). The
phase space data of the valid PG detection events is called PG phsp data in the following.
Considering the huge computational resources needed to generate enough PG phsp data,
only 20 PBs were simulated from a given TP, as presented in section 5.1. For each PB, 100
statistically independent simulations, each of 1× 106 primary protons, were conducted in
parallel. Besides, simulations using 1.35× 108 protons are performed as this value is set to
the PG detectability threshold in the first part of this work.
In addition to Geant4, calculations of dose and PG emission and detection were also
performed with the REGGUI platform in the last part of the work. For the dose cal-
culation, REGGUI integrates the Monte Carlo engine MCsquare, which was designed
and optimized for the last generation of Intel Xeon processor and Intel Xeon Phi co-
processors for fast MC dose simulation (Jeffers & Reinders 2013, Wang et al. 2014, Schulz
et al. 2012, Rahman 2013). Heavy charged particles, e.g. protons, deuterons and alphas are
simulated using the class-II condensed history algorithm (Salvat et al. 2011, Geant4 2013).
Hard ionizations, with energy losses above a user-specified threshold, are simulated indi-
vidually while the soft events are regrouped in a multiple scattering theory. Cross sections
from ICRU 63 (Malmer 2001) are used for the sampling of the elastic and inelastic nuclear
interactions.
The MC engine used for the construction of the analytical computation of PG emission and
detection [Sterpin et al., 2015] is the extension of PENELOPE (Salvat et al. 2011) to pro-
tons, called PENH (Salvat 2013, Sterpin et al. 2013, Sterpin et al. 2014). PENH simulates
nuclear reactions using the cross sections from ICRU 63 (Malmer 2001) for interaction of
protons with elements that have a weight contribution of more than 1% to human tissues,
i.e. 12C, 14N, 16O, 31P and 40Ca (Sterpin et al. 2013). Elastic and inelastic electromagnetic
collisions are calculated by a mixed (class II) algorithm (Salvat et al. 2011, Salvat 2013).
4.1.3 MC TP using CERR
TPs in this work are created using the particle extension of CERR which is an open source
environment for TP researches based on Matlab (version 2014).
To make a MC TP using CERR (Resch et al. 2017), the patient CT as well as the
contouring of the organs are firstly imported (figure 4.2). In this work, the planning tar-
get volume (PTV) is set to the default PTV in the corresponding scenario in the initial
photon plan. To reduce the computational resources needed for the TP, the OAR for the
TP optimization is set to a 1 cm ring surrounding the PTV (TP OAR, an example is
shown in figure 4.2, red region), instead of using the ones defined for critical structures
(clinical OAR) which are used only for evaluation. The prescription dose is set to 2 and
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Figure 4.2: The interface of CERR TPS. The patient CT, organ contouring (in this example
the PTV TP OAR of H&N1) and exemplary PB MC dose used for the MC TP optimization
process are shown.
0 Gy for the PTV and TP OAR, respectively. The TP optimization (see equation 2.12)
penalty factors for the PTV and TP OAR are set to 10000 and 10, respectively. Given the
angle(s) of the treatment field(s), all the variables used for the TP optimization, such as
PB grid (PB spacing: 5 mm), dose vectors etc., are initialized by the CERR platform. TP
fields are set to two (angles of 260◦ and 100◦), two (90◦ and 270◦), two (45◦and 270◦), one
(315◦) and two (90◦ and 270◦) for the patient H&N1, H&N2, H&N3, H&N4 and PROST1,
respectively. Files needed for the Geant4 simulation, e.g. PBs settings and geometry are
then exported by CERR. MC dose, PG emission and LETd distribution data are then
generated by Geant4 simulation for each individual PB. The generated Geant4 dose files
are imported to CERR and the MC TP is created by optimizing equation 2.12 using a
gradient descent algorithm.
Although in this work radiobiological considerations have been restricted to the evaluation
of LETd distributions, it is worth mentioning that CERR is also able to create TPs using
biological dose based on different relative biological effectiveness (RBE) models (Resch
et al. 2017).
4.1.4 Camera response simulation based on REGGUI
REGGUI is an image processing open-source platform for adaptive proton therapy based
on Matlab (Janssens et al. 2009, Kurz et al. 2015). It allows the import of CT images, TPs,
contours etc for further workflows, e.g. for PG simulation (both emission and detection).
In particular, for the workflows developed for all investigations using multiple CT datasets
of a given patient, REGGUI is firstly employed to register the CTs at different time points
for the same patient, thus all the CTs for the same patient have the same isocenter and
coordinate system.
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For the last part of this work, addressing the response of a realistic PG detector, the
Figure 4.3: Schematic description of the PG imaging system used in REGGUI. Emitted PG
are collimated by a knife-edge slit collimator and imping on LYSO crystals. The nominal
magnification factor for the given geometrical distances is 0.8 (Sterpin et al. 2015).
spot-by-spot dose distribution is generated using REGGUI based on MCsquare (Souris
et al. 2016). The PG emission and PG detection using the knife-edge camera (Perali
et al. 2014), consisting of a photodetection system and a knife-edge slit tungsten colli-
mator mounted on a dedicated trolley positioning system (see section 3.1.1 in chapter 3),
is simulated using the REGGUI-PG package developed by (Sterpin et al. 2015). Since
a full blown MC simulation is computationally expensive, the REGGUI software firstly
calculates the 1D PG emission using a pre-computed MC simulation (based on the PENH
extension to PENELOPE introduced in section 4.1.2) of the PG emission along the pro-
ton track as a function of incident proton energy and tissue composition. The emission
information is recorded in terms of the spectrum of protons (from 3 to 8 MeV in 1 MeV
steps). The PG emission is then converted to the detection using a convolution of the
physical PG emission with the camera response depending on the geometry (target, PG
camera position). The effects of self-absorption in the target, the camera optical effects,
i.e. the magnification factor, and the interaction between high energy gammas and mat-
ter, i.e. photo effect, incoherent scattering as well as pair production are included in the
convolution kernel (Sterpin et al. 2015). The simulated camera (figure 4.3) relies on 504
cm3 of lutetium-yttrium oxyorthosilicate scintillating crystals distributed over 2 rows of 20
slabs vertically aligned one on top of the other. Each slab is 31.5 mm thick, 100 mm high,
4 mm in width along the beam axis, and together with its mirror slab in the other row,
constitutes one of the 20 bins of the 1D detection. The field-of-view (FOV) of the camera
can be adjusted by modifying the distance from the center of the collimator to the center
of the detector crystals and/or the distance from the center of the collimator to the beam
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axis. On the beam axis, a total of 100 mm FOV is covered by the crystals. The energy
detection window is set to 3-6 MeV (Perali et al. 2014, Sterpin et al. 2015, Xie et al. 2017).
4.2 Spot aggregation and TP re-optimization
Sufficient statistics is required for PG imaging. In traditional TP, only a few PBs reach
such PG detectability threshold (figure 4.4).
Figure 4.4: Statistics of PBs in the CERR initial TP for one of the investigated H&N
cancer patients. Only 12 PBs have more than 1.35×108 protons among the 3811 PBs used.
Hence, the majority of the PBs are not guaranteed to be detectable and to provide reliable
information for PG imaging.
4.2.1 Spot aggregation
In the work of (Xie et al. 2017), the lateral spacing between PBs is 5 mm, while the
individual PBs have a Gaussian-shaped lateral profile with 5-6 mm sigma, thus PBs are
overlapping through part of their distribution. To achieve the required statistics for reliable
PG monitoring with the used knife-edge camera, PBs nearby are aggregated (cf. section
3.2 and 5.2) at the cost of degradation in lateral spatial resolution. It has been shown that
a sigma value of 4-7 mm for the Gaussian-weighted aggregation has only a limited impact
on the lateral spatial resolution (reduced from 5 mm to 8.6 mm) but achieves improved
signal to noise ratio. Reproducibility studies with both simulated and measured data show
that precision better than 2 mm can be achieved for a large proportion of spots for aggre-
gated counting statics exceeding 2×108, with only a small reduction in lateral resolution.
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However, the work of (Xie et al. 2017) was conducted for a relatively homogeneous case
of a brain tumor. In a more complex target with greater tissue inhomogeneities, spot ag-
gregation will require careful spot selection and unavoidable range mixing will have to be
taken into account in the data analysis (Xie et al. 2017).
4.2.2 TP re-optimization
An alternative novel approach is proposed in this work to re-optimize the TP by boosting a
few selected reliable PBs which are not significantly affected by the tissue heterogeneities.
More details and the comparison to the spot aggregation are described in chapter 5 and 6.
4.3 Basic concepts of machine learning
A basic machine learning (ML) model, neural network, is used in this study for the pat-
tern recognition of PG profiles. Unlike traditional analytical approaches which are sets
of explicitly programmed instructions, machine learning trains the algorithms on data in-
puts and use statistical method in order to output values that fall within a specific range,
usually the maximum likelihood estimation. A deeper introduction to this method can be
found in (Goodfellow et al. 2016), while the basic ideas are summarized in the following.
4.3.1 General idea of machine learning
In principle, the data used for the ML model optimization are divided into three indepen-
dent data sets: training, validation and test dataset.
The model is initially fit on a training dataset (James et al. 2013), which is a set of ex-
amples used to adjust the parameters of the model. Successively, the validation dataset
is provided to the fitted model, thus the model is evaluated using a cost function. The
purpose of using independent datasets for fitting and evaluation is to avoid overfitting (see
figure 4.5). The ML model is then kept fitted using training dataset until the cost calcu-
lated using the validation dataset has been minimized. Finally, the fully trained model is
output and can be used for the prediction of the new data. An unbiased evaluation of the
final model is given by the cost function calculated using the test dataset. The workflow
is shown in figure 4.6.
Depending on the form of the data provided for the training, ML algorithms are classified
into mainly supervised learning and unsupervised learning.
Supervised learning
The input data provided to the machine learning are labeled with the desired
output. The idea is to train the model to evolve by minimizing the difference
between its prediction (or guess) and the actual output until this difference is
acceptable. The fully trained model can be then used to predict the label of
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Figure 4.5: An exemplary training set and validation set from the same statistical popu-
lation are shown as black spots. Two predictive models (blue and red) are fitted to the
training dataset (spots shown on the left). The sum of squared errors (SSE) between the
training dataset and the fit 1 / fit 2 are 21.5 / 34.6, respectively. This means that if the
cost function was calculated using training data, fit 1 would be identified as being better.
The SSE between the validation dataset (spots on the right) and the fit 1 / fit 2 are 101.2
/ 28.6, respectively. Thus the fit 2 would be favoured by this approach. The red curve
overfits the training data much less since it matches both training and validation datasets
Figure 4.6: Schematic workflow of machine learning training. The model is only changed
in the training data (fit) step.
new unlabeled input. This type of machine learning consists of reggression and
classification (Alpaydin 2010).
Unsupervised learning
The input data provided to the model are not labeled. The algorithm is ded-
icated to search potential patterns in datasets without pre-existing labels. It
is also known as self-organization and allows modeling probability densities of
given inputs (Hinton & Sejnowski 1999). Two of the main approaches are prin-
cipal component (Pearson 1901, Hotelling 1933) and cluster analysis (Garfinkel-
Castro et al. 2020).
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4.3.2 Introduction of neural network algorithms
This work uses only supervised neural network learning for classification (figure 4.7).
Neural network learning (NNL) is used to extract potential logic behind a group of known
Figure 4.7: Schematic structure of neural network learning. The sizes of the input layer
and output layer are the same as the sizes of input data and the label, respectively. The
sizes and number of the hidden layers are assigned by the user.
data Ai (ai,1, ai,2, ..., ai,n) and known label Bi (bi,1,bi,2, ..., bi,m), and then predict the
result Y (y1, y2, ..., ym) of new unlabeled input X (x1, x2, ..., xn) under the same logic.
The basic neural network used in this study, also called artificial network, consists of one
input layer (one vector), hidden layers (one or more vectors), and one output layer (one
vector). The lth vector Vl and the (l + 1)th vector Vl+1 are linked by a matrix Wl,l+1, and
a bias vector Bl,l+1 as well as a nonlinear function (called activation function) fl,l+1:
Vl+1 = fl,l+1(V
′
l+1) (4.1)
in which V ′l+1 equals the dot product of Wl,l+1 and Vl plus the bias vector Bl,l+1:
V ′l+1 = Wl,l+1 · Vl +Bl,l+1 (4.2)
There are different types of activation functions such as sigmoid (f(x) = 1/(1+e−x)), tanh
(f(x) = tanh(x)), ReLu (f(x) = max(0, x)) etc. The selection of the activation depends
on the task of the machine learning and a tradeoff between efficiency and accuracy has to
be made. The ReLu function is a general activation function and is used more and more
nowadays.
The logic behind the known input Ai and label Bi is discovered and stored in the model
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structure along with all those weight matrices and bias vectors via the training process.
The fully trained model is then used to predict the label of the new input in the application
process. To create a NNL model, the NNL structures (e.g. activation function types, size
and number of the relevant layers etc) is firstly assigned by the user. The size of the input
layer and output layer is set to the same size as the input data and the label, respectively.
The number and sizes of the hidden layers are assigned by the user, depending on the
task and the performance of the model. The values in the weight matrices and bias layer
vectors are initialized randomly (usually from 0 to 1). The input layer L1 is set to the
example data Ai and all the values of other layers are calculated using function 4.1 and
4.2. The output layer, called Oi, is thus obtained and is compared to the label Bi using a
loss function:
LOSS = LossFun( ~O, ~B) (4.3)
in which
Oi = NNL(Ai) (4.4)
The most commonly used loss function is the sum of squared errors function:
LossFun( ~O, ~B) =
∑
i
(Oi −Bi)2 (4.5)
where Oi is calculated by a batch of inputs randomly chosen from the training dataset and
Bi are the corresponding labels.
The model is then optimized by changing the values of the weight matrices and bias vectors
using a gradient descent algorithm:
Mi+1 = Mi − λ
∂loss
∂Mi
(4.6)
in which λ is the step size of the optimization, assigned by the user.
The data from the input dataset are kept feeding to the optimization until the loss calcu-
lated using the evaluation dataset meets the stopping criterium set by the user.
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Chapter 5
Introducing an innovative treatment
planning concept including PG
monitoring
The statistics of the PB will affect the precision of PG due to fluctuations of the signal
and random noise. Enough statistics is needed to generate smooth PG profiles for proton
range verification. Besides, in ideal cases when a PB is delivered to a homogeneous target,
the distance between the falloff of the laterally integrated PG and dose profiles is a small
value, thus it is possible to infer the dose falloff from the PG falloff. However, in real
clinical scenarios this conformity might be deteriorated due to e.g. tissue heterogeneities.
The degree of conformity (called PG-dose correlation in the following) between the dose
and PG falloffs, and the robustness to tissue heterogeneities are quantified in this thesis.
The main idea of this work is to identity PBs which can carry useful information for proton
range verification and provide them with enough statistical weight for reliable PG imaging,
while not deteriorating the dosimetric quality of the TP.
5.1 Effect of the PB statistics on the precision of the
PG signal falloff
Profiles of PGs at emission and detection with different statistics are generated by summing
a different amount of independent MC simulations (cf. section 4.1.2). For example, the
profiles of 107 primary protons are generated by summing up the results of 10 independent
simulations of 106 protons each, thus 10 profiles of 107 protons can be generated using
the 100 independent simulations. The profiles of PG emission and detection with different
statistics are compared in figure 5.1. It can be seen that the PG detection data are highly
sensitive to the statistics of the incident protons.
The precision of the PG distal fall-off signal, defined as the standard deviation of the
falloffs of the PG detection profiles generated by independent MC simulations for the same
PB, is shown in figure 5.2 as a function of primary protons. A precision of 1 mm can be
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Figure 5.1: Laterally integrated depth profiles of the PG detection and PG emission dis-
tributions are shown on the left and right panel, respectively.
achieved when the number of protons of an individual PB is higher than 1.35× 108. Only
a few PBs can reach such high statistics in a traditional TP cf. figure 4.4 in section 4.2.
Figure 5.2: Standard deviation of the PG distal falloff based on PG detection data from
different number of incident protons and statistically independent MC simulations. (Tian
et al. 2018)
5.2 TP re-optimization to achieve sufficient statistics
for PG imaging
CERR uses function 2.12 to optimize the TP. To boost the statistics of selected PBs above
the statistical threshold wboost, an additional particle number lower bound of wboost is set
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for the selected PBs, while 0.5 (in unit of 106 protons, cf. section 2.2) is set for the other
PBs (considering the detectability threshold and the typical sensitivity of beam monitor
systems in pencil beam scanning (Hernandez 2017)).
As a comparison, the alternative approach of PB aggregation proposed by (Xie et al. 2017)
has been investigated in this work using the PB statistics from the initial CERR TP. The
Gaussian kernel, normalized such that the weight of the central PB is one, was set to have
a standard deviation of 7 mm, as used in the work of (Xie et al. 2017). The same PBs
selected in the TP re-optimization are aggregated using corresponding nearby PBs within
the range of 2 sigma, i.e. 14 mm:
PGaggregation =
∑
i
wi · φi · PGi (5.1)
where wi is the weight of the nearby PB i in the initial CERR TP, PGi is the corresponding
PG emission profile obtained from MC simulation (where the same statistics of 5 × 105
primary protons is used for every simulated PB) and φi is the Gaussian weight of the i-th
PB.
5.3 PB selection for boosting accounting for the con-
formities between PG and dose signal
5.3.1 Quantification of the conformities between PG and dose
signal
Figure 5.3 shows an example where the PG-dose correlation is deteriorated by the tissue
heterogeneities, meaning that the distal falloffs of the dose and PG laterally integrated
depth profiles do not match well.
There are two approaches to analyze the correlation between the laterally integrated
profiles of the PG (emission) and dose, which requires the identification of the falloff
relative or absolute position: shifting (Knopf et al. 2009, Helmbrecht et al. 2013, Frey
et al. 2014) and fitting (Janssen et al. 2014). The shifting method, requiring at least two
profiles of the same quantity to be compared, is used in this work to determine the shift of
the profiles of dose and PG of the PBs on different CTs. The fitting method, applicable
to a single PG profile, tries to recognize and analytically describe the falloff pattern of the
PG signal. The PG-dose correlation is identified by comparing the falloffs of the dose and
PG. The first part of this work focuses on the PG-dose correlation using only CT1, thus
the fitting method is applied. The shifting method will be used in the next part of this
work, where the PG and dose profiles on CTs at different time points are compared.
The dose falloff position is defined by the 80% distal falloff of the laterally integrated depth
dose profile (Paganetti 2018). An ideal PG signal falloff, e.g. occurring when the PB is
delivered to a relatively homogeneous tissue, consists of a distal gradual tail and a sharp
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Figure 5.3: Dose distribution (in colourwash) of two PBs in the patient X-ray CT (gray
scale) are shown on the left, while the laterally integrated profiles of dose, PG emission
and ideal PG detection of the corresponding PBs are shown on the right. The PB on the
top is affected by tissue inhomogeneities, such that the Bragg peak is distorted and the
correlation between the falloffs of the dose and PG is poor. For the PB on the bottom,
the falloffs of the PG profiles, both emission and detection, well correspond to the falloff
of dose, thus it is possible to verify the dose falloff from the PG signal.
falloff connecting the tail and the main part of the PG profile (figure 5.4.A). A sigmoid
function:
f0(x) = a+ (1− a) · erf [b · (x− c)] (5.2)
is employed to fit the falloff of the PG profile (Janssen et al. 2014). The position of the PG
falloff is defined by the center of the fitting curve, c. In the case of a relatively homogeneous
tissue (figure 5.4 A), the tail makes little contribution, thus the fitting describes the falloff
well. However, due to tissue heterogeneities near the Bragg peak, the PG falloff could be
more complex, affecting the PG-dose correlation (figure 5.4 B, C and D).
Three criteria are proposed for the quantification of the PG-dose correlation:
1. The distance between the falloffs of PG and dose. In the case of homoge-
neous tissue, this distance is supposed to be a fixed small value such that the
proton range, i.e. dose falloff, could be inferred knowing the PG falloff. Let Ri
be the distance between the falloff of the dose and PG of PB i. This criterion
is defined by ∆Ri = |Ri − Rmode| in which Rmode is the mode estimation of all
Ri of the PBs used in the TP.
2. The slope of the sigmoid fitting curve bi of PB i. A gradual falloff means that
the energy deposition is not concentrated in space due to low density medium
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Figure 5.4: Typical examples of laterally integrated PB profiles of the PG and dose distri-
butions calculated in a CT of a head and neck tumour patient to demonstrate the criteria
quantifying the PG-dose correlation. A) The PB is delivered to a relatively homogeneous
tissue. The fitting curve has a sharp falloff and the PG falloff position is close to the dose
falloff. B) The distance between the falloffs of the PG and dose is large. C) The slope of
the fitting is gradual, leading to a potentially unreliable PG-dose correlation. D) The sum
of squared errors (SSE) between the fitting and PG is large, due to a distal peak caused
by tissue heterogeneities.
or tissue heterogeneities, thus the Ri of this PB is not reliable.
3. The SSE value between fitting and the PG falloff. This criterion describes
the reliability of the fitting method for the given PB.
5.3.2 PG falloff pattern recognition
To properly fit the falloff of the PG profile, the falloff region has firstly to be recognized.
Considering the complexity of PG profiles in the case of a head and neck cancer patient, a
pattern recognition algorithm is developed for the falloff identification of PG, unlike tra-
ditional fitting methods. Examples are shown in figure 5.5.
First of all, the PG profile is smoothed and linearly normalized to a maximum value of 1.
The region of interest is defined from the most distal peak which is above 0.8 (called Xstart)
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to the most distal point above 0.05 (called Xend). A new fitting function f1(x) consisting
of a sigmoid function (see formula 5.2) fs(x) and a distal Gaussian function fG(x) is used
to fit the region of interest :
f1(x) = fs(x) + fG(x) (5.3)
in which
fs(x) = a+ (1− a) · erf [b · (x− c)] (5.4)
fG(x) = d · exp[−(x− e)2/2f 2] (5.5)
where coefficient c in fs(x) and e in fG(x) fulfill:
e− c > FWHM/2 (5.6)
thus the Gaussian peak is always distal and a proper distance is guaranteed. The FWHM
is the full width at half maximum of the Gaussian function fG(x):
FWHM = 2.35482 · f (5.7)
Combining the formulas ( 5.3)-( 5.7), the final fitting function for the region of interest is:
f1(x) = a+ (1− a) · erf [b− (x− c)] + d · exp[−
2.354822 · (x− c− ε)2
8(ε− λ)2
] (5.8)
with constraints ε > 0 and λ > 0. Here the coefficients e and f are calculated by ε and λ
to simplify the coding script. The fitting f1(x) as well as the sigmoid fs(x) and Gaussian
fG(x) components are shown in the top raw of figure 5.5 in red and blue, respectively.
Two falloffs are provided by the sigmoid and Gaussian components of f1(x) fitting. Falloff1
is given by the sigmoid function, starting from Xstart to the lowest point X1 in [Xstart, c+ε].
The falloff2 defined by the Gaussian formula starts from the highest point in [X1, Xend] to
the end of the region of interest Xend. Either falloff1 [Xstart, X1] or falloff2 [X2, Xend] is
possible to be the true falloff of the entire PG profile which best matches the dose falloff
(see middle row in figure 5.5).
Identifying the falloff region of PG is simple when the dose profile is available, i.e. at the
planning stage:
Fselect(PGplan, doseplan) =
{
0, falloff1 is closer to the dose falloff
1, falloff2 is closer to the dose falloff
(5.9)
Note that the dose profile is assumed to be unknown for the measurement data, i.e. when
the PG is used to infer the dose falloff (MC recalculation in this work, where the PG
profiles are called PGrec). A supervised neural network (cf. chapter 4) learning model is
built for the falloff identification in this case:
Fselect(PGrec) = NNLapp(PGrec,W,B) (5.10)
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Figure 5.5: Three examples of how the pattern recognition based fitting method works. f1
fitting is shown on the top row. The identification of the falloff region is demonstrated in
the middle row. In the last step, the sigmoid fitting f0(x) is applied to the falloff region
as shown by the bottom row.
in which the NNLapp is the neural network model while W and B are the weight matrices
and bias vectors trained using the data generated in the planning stage (labeled using
function 5.9): {
W
B
= NNLtrain(PGplan, doseplan) (5.11)
The input vector consists of: 1) The heights of both falloffs; 2) The slopes of both falloffs;
3) the distance between the Gaussian and sigmoid functions; 4) whether the falloff1 is
proximal to the weighted average position [
∑
x · PG(x)]/
∑
x of the entire PG profile
(boolean), in which x and PG(x) are the position in depth and PG value.
Two hidden layers (the first one has 14 arguments and the second one has 6 arguments) are
employed in this work. All the activation functions are set to the sigmoid function (f(x) =
1/[1+exp(−x)]). The logic of this NNL is simple: a falloff with steep slope and pronounced
height is preferred. Similar settings of the hidden layer, e.g. two hidden layers of 10 and
8 arguments, do not significantly affect the performance of the NNL. However, since this
is a very simple NNL model based on rather intuitive criteria, the size and numbers of
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the hidden layers should not be too large so that potential optimization problems e.g.
in gradient descent (Ruder 2016) and exploding gradient (Pascanu et al. 2012) could be
avoided.
The output layer has only one argument. Falloff2 is selected when the output is above
Figure 5.6: Workflow of the pattern recognition based fitting method. (Tian et al. 2018)
0.95 while falloff1 is selected when the output is lower than 0.05. For some exception
cases listed below, the falloff1 and falloff2 are merged and the falloff region is set to the
combination [Xstart, Xend]. The PG-dose correlation degree can be easily identified by the
slope and ∆Ri in those cases:
1. The Gaussian function is not necessary for the fitting of the region of in-
terest, characterized by: (a) overlapping of falloff1 and falloff2, (b) a very low
Gaussian peak, (c) a short distance between the Gaussian and the sigmoid
function, and (d) a narrow Gaussian peak.
2. f1(x) fitting fails, showing a large SSE value (top 10% of the highest SSE
values). The initial idea of introducing an additional Gaussian function is to
better fit the potential distal peak affected by relatively simple tissue hetero-
geneities. This approach would fail when the tissue heterogeneities are more
complex, i.e. the PG-dose correlation is poor. In this case the combination of
falloff1 and falloff2 is regarded as the falloff region and the corresponding PB
can be easily identified as poor PG-dose correlation in the following process.
3. An output of NNL between 0.05 and 0.95 suggests that NNL cannot select
a dominant falloff among the competitive falloff1 and falloff2.
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Finally, the conventional sigmoid function f0(x) is applied once the falloff region has been
identified and the falloff position is given by the parameter c. The exemplary algorithm
and the workflow are shown in figure 5.5 and 5.6 respectively.
5.3.3 PBs selection accounting for PG-dose correlation
Considering the uncertainties of the range for those boosted PBs which will deliver high
dose, only PBs with maximum proton energy which have their Bragg peak in a safety
region inside the PTV planning target volume (i.e., within an inner safety margin of 1.5
mm from the edge of the PTV) are evaluated in terms of PG-dose correlation. PBs with
small ∆Ri (less than 2.5 mm), steep slope (b < −1/5) and small SSE value (not top 33%
of the highest SSE values) are identified to have a good PG-dose correlation. Additionally,
PBs which have an air cavity in the Bragg peak region, i.e. CT numbers lower than -700 in
a region within 2 mm range of the highest dose point, are discarded. Considering that the
statistics of the selected PBs would become obviously higher than that used in the initial
CERR TP, PBs are divided into different geometrical groups to avoid possible Bragg peak
overlap so that hot spots are avoided. In this work, five PBs per field are selected among
those with good PG-dose correlation from four nonadjacent outer groups and a random
inner group (see figure 5.7).
5.4 Comparison of the re-optimized TP and initial
CERR TP
In this work, the Geant4 based MC TPs (see chapter 4), called in the following initial
CERR TPs, for three head and neck cancer patients (H&N1, H&N2 and H&N3), each
with two treatment fields, are re-optimized by boosting 5 spots with good PG-dose corre-
lation per field. The prescription dose is set to 2.0 Gy. For each patient, the re-optimized
TPs are created by setting the wboost to 1.35e8. The initial CERR TPs and re-optimized
TPs are recalculated on the patient CTs using Geant4 and compared in terms of dose dis-
tribution, LETd distribution, TP robustness to range uncertainties and translational setup
errors, as well as spot-by-spot PG-dose correlation.
5.4.1 Dose distribution
The 3D dose distributions along with the dose-volume histograms (DVH) of targets and
clinical OAR of all TPs created are compared in figure 5.8 and 5.9. The dose delivered
by the initial CERR TPs and the re-optimized TPs is comparable. The statistics of the
boosted PBs is above the set wboost (1.35× 108) and the corresponding Bragg peaks are in
the PTV and near the PTV margin. The maximum dose delivered by the boosted PBs in
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Figure 5.7: The PBs selection for boosting. A) Beams-eye-view (BEV) of the TP. The
blue spots are the maximum energy PBs which have Bragg peaks inside the selected safety
region within the PTV, while the red spots refer to the PBs covering the edge of the target,
whose Bragg peak is outside the PTV on the given CT. B) The PBs available (blue spots
in (A)) are divided into 10 equivalent geometrical groups (yellow and green spots). The
red ring is a margin which separates the inner and outer zones. C) PBs are evaluated in
terms of PG-dose correlation. The blue spots are presented to the user for selection. The
solid blue spots are the PBs selected and boosted in this re-optimized TP. D) The dose
distribution of a given PB can be shown if needed. (Tian et al. 2018)
the re-optimized TP is 0.59, 0.61, and 0.88 Gy for the three patients.
5.4.2 TP robustness
The robustness of the initial CERR TPs and re-optimized TPs are evaluated on patient 1
using MC simulations considering (1) range uncertainties of ca. ±3% by changing the CT
numbers by ±3% and (2) setup uncertainty of ±3 mm by shifting the patients CT image
along the x, y, z axis respectively. Figure 5.10 shows the DVHs of the TPs simulated under
different uncertainties. The robustness of both plans is found to be comparable, with DVH
curves of the targets overlapping and comparable trend for the clinical OARs, notably with
a tendency to lower dose in the re-optimized TP.
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Figure 5.8: The CT scan (gray scale) with superimposed dose distribution (colourwash)
of the initial CERR TPs (left column), the boosted PBs (middle column), and the re-
optimized TPs with wboost of 1.35 × 108 (right column) for three head and neck cancer
patients. The scale and maximum dose values are shown next to the color bar. (Tian
et al. 2018)
5.4.3 Dose averaged LET distribution
Considering the ability of CERR to create TPs based on different RBE models (Resch et al.
2017), which depend on the LET distribution (cf. section 2.1.1), LETd is recorded during
the MC simulation of the TPs. The initial CERR TPs and re-optimized TPs for the three
considered patients are compared in terms of dose averaged LET in figure 5.11. Both TPs
are found equivalent with deviations of the maximum LETd values within approximately
2.1%.
5.4.4 Spot-by-spot PG-dose correlation and statistics
The BEV of the individual fields for the TPs created are shown in figure 5.4.4, where the
spot-by-spot statistics and ∆Ri (see 5.3.1) of the corresponding PBs are illustrated by the
dimension of the symbols and colour-coded. The spots with red rings are the top 5 PBs
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Figure 5.9: The DVHs of the initial CERR TPs (initial plan) and the re-optimized TPs
(opt plan) are compared. (Tian et al. 2018)
with the highest statistics in the field.
In the initial CERR TP, the distribution and the PG-dose correlation of the highest-
statistics PBs are random and not imposed, but resulting from the optimization process.
In the re-optimized TPs, a few PBs with good PG-dose correlation selected uniformly
across the fields are boosted and have the desired statistics. The maximum ∆Ri of the
highest-statistics spots in the initial CERR TPs is more than 10 mm while this value is
lower than 3 mm in the re-optimized TP.
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Figure 5.10: The DVHs of the initial CERR TP and re-optimized TP are compared con-
sidering both range uncertainties (left) and setup uncerntainties (right). Only the upper
and lower bounds among all cases instead of all the curves are shown. Note that the solid
and dashed red lines almost overlap. (Tian et al. 2018)
5.5 The robustness of the PG-dose correlation in the
case of anatomical changes
In the previous study, only systematic range changes and positional (translational) errors
were addressed, not accounting for the effect of unpredictable anatomical changes which
can occur over the course of fractionated radiation therapy. To further investigate this
effect, the dose and PG emission of PBs used in the TPs for one head and neck (H&N4, 1
field) and one prostate cancer patients (PROST1, 2 fields) are simulated on CTs acquired
at three time points to evaluate the performance of the PG-dose correlation indicator, and
devise an extension which better accounts for anatomical changes.
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Figure 5.11: Dose average LET maps of the initial CERR TP and re-optimized TP (left)
and the comparison between both TPs in terms of LETd volume histograms (right). The
initial and the re-optimized TPs are equivalent as the volume histograms overlap. The
differences between the maximum dose averaged LET values of different TPs are approxi-
mately within 2.1%. (Tian et al. 2018)
5.5.1 Shifting method
To quantify the effect of anatomical changes on the PG signal, the PG emissions on different
CTs of the same patient for the same PB are compared with the shifting method described
in the following, and thereby the relative shift of the PG distal fall-offs is obtained. These
shifts are then compared to the shifts of the fall-off of the dose profiles on the corresponding
CTs, also devised from the shifting method. The difference between the shifts of the
profiles of dose and PG on different CTs describes the degree of reliability of PG imaging
as surrogate of the dose delivery for a given PB under consideration of anatomical changes.
The shifts of PG/dose laterally integrated depth profiles are calculated by minimizing the
SSE value between the profile on CT1 and the shifted (step size: 0.01 mm) profile on CT2
in a given distal fall-off region (figure 5.13). For the dose, the distal fall-off region is taken
from the max value to the end of the profile. For PG profiles, the fall-off identification
follows the same approach described in section 5.3.
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Figure 5.13: Exemplary shift calculation for the laterally integrated depth profiles of dose
(left) and PG emission (right) on CT1 (red) and CT2 (blue). The shifted dose/PG profiles
of CT2, which yield the minimum SSE value compared to the profiles on CT1, are shown
in green. (Tian et al. 2020)
5.5.2 PG-dose correlation in presence of anatomical changes
Figure 5.14 shows the PG-dose correlation quantified as the ∆Ri (cf. section 5.3.1) on CT1
as well as the difference of the shift of the dose and PG on CT1 and CT3 for one head and
neck patient (H&N1). The PG-dose correlation of a PB might change due to anatomical
changes, e.g. the spot with a red circle shows good PG-dose correlation on CT1, however
the PG-dose correlation on CT3 changes and thus the shifts of the dose and PG do not
match.
The anatomical changes, especially for tissue in heterogeneous regions, could signifi-
Figure 5.14: The PG-dose correlation quantified as the ∆Ri on CT1 is shown in the BEV
on the left side, while the shift difference of the dose and PG on CT1 and CT3 are shown
on the right. The ∆Ri and shift difference values are color coded. The details of the PG
and dose profiles of the spot with the red circle are shown in figures 5.15 and 5.16
cantly change the PG-dose correlation in different CTs representing variations of patient
anatomy during the course of fractionated therapy. Hence, these findings motivated the
development of a new indicator to account for the effect of the tissue heterogeneities, as
addressed in the next section.
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Figure 5.15: Dose distribution of the spot marked with a red circle in figure 5.14, calculated
on CT1 and CT3. Note that the shape of the air cavity has changed and thus the dose
distribution is affected.
5.5.3 Quantification of the effect of tissue heterogeneities
Dose surface indicator
It was proposed by (Min et al. 2014) to quantify the effect of tissue heterogeneities by
using the distal 2D surface in a study of PET (cf. section 2.3.2) based range monitoring
for passively scattered proton beam delivery. A similar concept is introduced to estimate
the effect of tissue heterogeneities on the MC dose distribution of each individual PB in
Figure 5.16: The PG-dose correlation quantified from the PG fitting and 80% dose value
on CT1, the shift of the dose profiles (-6.2 mm) as well as the shift of the PG profiles (-13.3
mm) on CT1 and CT3 for the metioned PB of figure 5.14 are shown on the left, middle
and right, respectively
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this study. This dose surface is calculated as follows: 1. The 3D dose distribution of the
PB is rotated such that the beam direction is along the left-right (LR) axis; 2. The rotated
3D dose matrix consists of dose voxel columns along the LR axis (figure 5.17 A). The 2D
dose resulting from the averaging of the 3D dose in beam direction is used to select dose
columns with a value higher than 50% of the maximum averaged dose; 3. The 80% distal
falloff position of the LR profile of each dose column is regarded as the range of this dose
column (all profiles have the same origin instead of patient surface so that only the geo-
metrical effect of the distal dose distribution, regardless of the penetration depth in tissue,
is accounted for); 4. For the 3D dose distribution of a given PB, a 2D surface is composed
of the range of each dose column (called dose surface). To further investigate the degree
of the tissue heterogeneity in the beam path, the CT numbers (HU) in the voxels within
the same dose columns but starting from the patient skin to the 80% distal dose falloff are
analyzed in terms of mean and standard deviation (std) values. These CT-based values
are not used for the PB identification but only for subsequent analysis.
The effect of tissue heterogeneities on the 3D dose distribution used for the PBs identifi-
Figure 5.17: 3D MC dose distribution of a given PB passing through (A) water and (B)
a relatively homogeneous tissue as well as (C) a pronounced heterogeneous tissue in the
pelvic region. The Sstd calculated values are 0.03, 0.50 and 2.8 mm for A, B and C,
respectively. The std values of the CT numbers in the beam path for A, B and C are 0,
199 and 219, respectively. (Tian et al. 2020)
cation is quantified by the standard deviation of the dose surface, Sstd:
Sstd =
√∑n
1 (rangei − rangemean)2
n− 1
(5.12)
where rangei is the range of the dose column i, rangemean is the mean value of the ranges
of all considered dose columns, and n is the number of the columns under consideration.
A small Sstd value means that the dose columns have similar ranges, i.e. the dose distribu-
tion of a given PB is not distorted due to the tissue heterogeneities (see figure 5.17 A and
B). Thus, the dose surface could be used as indicator of PBs more sensitive to anatomical
changes.
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5.5.4 PB selection accounting for the dose surface
The PG-dose correlation and the dose surface indicators are combined to select PG friendly
PBs for boosting (figure 5.18). The criteria for the PG-dose correlation are the same as
described in section 5.3. For the dose surface indicator, the threshold of the Sstd value is
set to 1.5 mm, slightly higher than the desired PG precision of 1 mm, based on the dis-
tribution of the Sstd values of the PBs investigated. Considering the potential anatomical
changes, e.g. the movement of heterogeneities, only PBs with small Sstd values, and which
are surrounded by other PBs with acceptable Sstd, i.e. PBs whose center does not fall
within a 5 mm safety ring of any PB with a Sstd value larger than 1.5 mm, are suggested
for selection. The value of the safety margin of 5 mm is set the same as the spacing between
PBs used in the TP.
For each field of the considered patients, 5 PBs recommended by the new approach (called
Figure 5.18: The PBs selection combining the PG-dose correlation (top left) and dose
surface (top right) indicators. The ∆Ri (top left) and Sstd (top right) are color coded and
the spots without a black circle are PBs recommended by the corresponding indicator. The
PBs selected and boosted in this study are shown on the bottom left (blue for good PBs
and red for counter-indicated PBs). The MC dose distributions of given PBs are shown on
the bottom right. (Tian et al. 2020)
good PBs in the following) and 5 counter-indicated PBs rejected by at least one indicator
are selected and boosted in the re-optimized TPs for comparison. The wboost is set to
1.8 × 108 and 2.0 × 108, which are values above the statistical threshold and do not spoil
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the TP for the investigated patient cases H&N1 and PROST1, respectively.
5.6 Comparison between the re-optimized TP and ini-
tial CERR TP
5.6.1 Total dose distribution
The 3D dose distribution of the initial and re-optimized TPs on all CTs are compared in
figure 5.19, 5.20 and 5.21. In this particular case of repeated CTs accounting for anatomi-
cal changes, the CTV (which describes the clinical extent of the tumour without additional
margins to account for uncertainties) was considered. The total dose distributions of all
re-optimized TPs, regardless whether good or counter-indicated PBs are boosted, are ob-
served comparable to the initial CERR TP, as the DVHs of all TPs almost overlap for the
same volume on the same CT scan. For the CT3 of the prostate patient, hot spots are
found at the same position for all TPs, however the DVHs are still comparable.
This result confirms the previous observations that boosting a few PBs above the statis-
tical threshold does not visibly change the TP in terms of the total dose distribution.
5.6.2 Dose averaged LET distributions
Figure 5.22, 5.23 and 5.24 compare the LETd distributions of all TPs optimized on CT1
and then recalculated on CT1, CT2 and CT3 of the above mentioned patients, generally
yielding similar LETd value distributions with deviations of the maximum values within
approximately 1.6%. This is comparable to the findings of the previous work (section 5.4)
that the plan re-optimization boosting a few PBs does not significantly change the dose
averaged LET distribution.
5.6.3 Shift of dose and PG on different CTs
The spot-by-spot shifts of the laterally integrated dose profiles on different CTs are com-
pared to the corresponding shifts of the laterally integrated PG profiles to evaluate if a PB
is reliable for PG-based proton range verification under given anatomical changes.
The comparison of the shifts as well as the proposed dose surface indicator are shown
in the figures 5.25, 5.26 and 5.27. Both PB boosting and spot aggregation (cf. sec-
tion 5.2) approaches are tested in terms of the dose/PG shift estimation for the selected
PBs, where recommended/counter-indicated spots are denoted with blue/red circles, re-
spectively. Detailed data of the boosted PBs (both good and counter-indicated) are listed
in tables 5.1- 5.4.
From the tables 5.1- 5.4, the maximum dose/PG shifts of good PBs are observed
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Figure 5.19: Total dose distribution of the initial CERR TP (left), TP boosting good PBs
(middle) and TP boosting counter-indicated PBs (right) for the head and neck cancer
patient, all optimized on CT1 and then recalculated on the three different CTs acquired
at different time points. The scale and maximum dose values are shown next to the color
bar. (Tian et al. 2020)
to be 5.2/5.2 mm and 4.2/4.1 mm for the head and neck and prostate cancer patient,
respectively. For the good and counter-indicated PBs, the largest difference between the
shift of the dose and PG profiles are 0.8 and 5.7 mm, respectively. It can be observed
in figure 5.25- 5.27 that all PBs whose PG and dose shift do not match, i.e. the solid
red/blue spots in the bottom middle and bottom right BEV, are found to have large Sstd
values (solid red spots in the bottom left) while the PBs recommended by the combined
indicators have small shift difference values and are thus more reliable for PG-based proton
range verification.
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Figure 5.20: Total dose distribution of the initial CERR TP (left), TP boosting good PBs
(middle) and TP boosting counter-indicated PBs (right) for the prostate cancer patient,
all optimized on CT1 and then recalculated on the three different CTs acquired at different
time points. The scale and maximum dose values are shown next to the color bar. (Tian
et al. 2020)
5.6.4 Tissue heterogeneity in the beam path
The CT scans with superimposed the dose distributions of two exemplary PBs (one good
and one counter-indicated) are shown in figure 5.28. The mean and std values of the CT
numbers in the beam path of all the boosted PBs are shown in table 5.5. The std values
of the CT numbers in the beam path of the counter-indicated PBs (mean of std: 268) are
higher than those of the good PBs (mean of std: 141) for the head and neck patient, while
for the prostate patient the CT numbers std values are more comparable for the good
(mean of std: 160) and counter-indicated (mean of std: 194) PBs. Hence, the good and
counter-indicated PBs do not necessarily correspond to traversed regions of low and high
tissue heterogeneity, respectively.
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Figure 5.21: The DVHs of the initial CERR TP (red), TP boosting good PBs (blue) and
TP boosing counter-indicated PBs (green) devised from the dose recalculated with Monte
Carlo on the CT1 used for planning (solid line) as well as on CT2 (dashed line) and CT3
(dotted line) acquired at different time points. The DVHs of the clinical target volume
(CTV), and nearby OARs of the head and neck patient are shown on the left while the
DVHs of the relevant volumes for the prostate patient are shown on the right. (Tian
et al. 2020)
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Figure 5.22: The dose averaged LET distribution of the initial TP (left), TP boosting good
PBs (middle) and TP boosting counter-indicated PBs (right) for the head and neck cancer
patient, all optimized on CT1 and then recalculated on the three different CTs acquired
at different time points. (Tian et al. 2020)
5.7 Comparison between the statistics of PB aggre-
gation and PB boosting
In the spot aggregation approach, the aggregated PG profile is compared to the dose of
the central PBs, hence it is necessary to check the statistical contribution c of the central
PB to the aggregation, calculated by:
c =
Ncenter
Naggregation
(5.13)
Naggregation =
m∑
i=1
φi ·Ni (5.14)
where the Ncenter and Naggregation are the statistics of the central PB and the aggregated
PBs, respectively. φi is the Gaussian weight cf. section 5.2 of PB i, Ni is its statistics in
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Figure 5.23: The dose averaged LET distribution of the initial TP (left), TP boosting
good PBs (middle) and TP boosting counter-indicated PBs (right) for the prostate cancer
patient, all optimized on CT1 and then recalculated on the three different CTs acquired
at different time points. (Tian et al. 2020)
the initial TP, m is the number of nearby PBs aggregated.
PBs aggregated, with the same incident energy, may have different ranges due to the tissue
heterogeneities. To evaluate this effect, the range (all profiles have the same origin) of the
dose profile of the central PB is compared to the ranges of each nearby PBs aggregated.
The maximum range difference of a given central PB and its nearby PBs is called range
mixing (∆Range) of this PB.
Table 5.6 and 5.7 evaluate the spot aggregation approach in terms of statistics, range
mixing and the contribution of the central PB for 15 recommended PBs and 15 counter-
indicated PBs from the initial TP for the H&N and the prostate cancer patient. The
statistics of the boosted PBs is always higher than the set wboost (1.8× 108 and 2.0× 108
protons for the H&N and prostate patient, respectively), while the statistics of the ag-
gregated PB is not guaranteed to exceed this value. The tissue heterogeneities have a
considerable effect on the PB aggregation as a maximum range mixing of 14.6 mm is ob-
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Figure 5.24: The LETd-volume histogram of the initial TP (red), TP boosting good PBs
(blue) and TP boosing counter-indicated PBs (green), all optimized on CT1 and then
recalculated on CT1 (solid line), CT2 (dashed line) and CT3 (dotted line). The DVHs
of the CTV and nearby OARs of the head and neck patient are shown on the left while
the DVHs of the relevant volumes for the prostate patient are shown on the right. (Tian
et al. 2020)
served. Furthermore, the statistics of the central PBs in the initial CERR TP is not always
high enough to contribute dominantly to the aggregation.
Though the performance of the spot aggregation depends on the specific TP and specific
PBs aggregated, it can be inferred from our investigations that using only the spot aggrega-
tion may not be sufficiently satisfactory. On the one hand, the statistics of the aggregation
might still not be above the PG detectability threshold. On the other hand, the spot
aggregation is limited by the effect of tissue heterogeneities, resulting in range mixing, and
loss of lateral resolution. Those two issues can be addressed by the PB boosting approach
proposed in this thesis work.
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Figure 5.25: BEV of the PBs used for the head and neck cancer patient. The shift com-
paring the dose on CT2/CT3 to the dose on CT1 is shown in the top row. The middle
row shows the corresponding PG shift. The dose surface is shown on the bottom left. The
bottom middle and bottom right BEV show the difference between the shift of the dose
and PG on the different CTs with respect to the initial CT1 used for planning. The spots
wih blue/red circles are the good/counter-indicated PBs boosted in the re-optimized TP.
(Tian et al. 2020)
5.8 Discussion
In this part of the work, two indicators are built to quantify the spot-by-spot PG-dose
correlation as well as the effect of tissue heterogeneities on the dose distribution. TPs
are re-optimized by boosting 5 selected PBs per field. The PG-dose correlation indicator
is tested using the MC recalculation data on the same patient CT and the dose surface
indicator is estimated from the MC simulation on CTs taken at different time points of the
same patient. The comparisons show that both the initial TPs and the re-optimized TPs
are comparable in terms of TP robustness as well as dose and dose averaged LET distri-
butions on all CTs of the corresponding patients used in this study. PBs recommended by
the proposed indicators are observed to have better PG-dose correlation on both planning
CT and CTs at different time points in the course of fractionated radiotherapy, as the
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Figure 5.26: BEV of the PBs used in the field 1 for the prostate cancer patient. The shift
comparing the dose on CT2/CT3 to the dose on CT1 is shown in the top row. The middle
row shows the corresponding PG shift. The dose surface is shown on the bottom left. The
bottom middle and bottom right BEV show the difference between the shift of the dose
and PG on the different CTs with respect to the initial CT1 used for planning. The spots
wih blue/red circles are the good/counter-indicated PBs boosted in the re-optimized TP.
(Tian et al. 2020)
largest dose shift observed is 5.2 mm and the maximum difference between the shift of the
dose and PG in the planning CT and additional CTs is 0.8 mm. Moreover, PBs boosted
are guaranteed to have enough statistics for PG detection. This new planning approach
inherently lends itself to the possible future implementation of range verification by first
delivering and reliably monitoring the boosted PBs, which are part of the TP, without
compromising the plan dosimetric quality. Furthermore, the concept proposed here in the
context of PG could also be applied to other technologies than PG imaging.
The boosting planning approach critically relies on the ability to identify those spots which
offer the best PG-dose correlation at the time of the initial planning. To this end, a machine
learning based pattern recognition algorithm was introduced to augment the traditional
fitting method for the falloff identification. The neural network was trained using more
than 10000 PBs with good PG-dose correlation. The accuracy of the algorithm was found
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Figure 5.27: BEV of the PBs used in the field 2 for the prostate cancer patient. The shift
comparing the dose on CT2/CT3 to the dose on CT1 is shown in the top row. The middle
row shows the corresponding PG shift. The dose surface is shown on the bottom left. The
bottom middle and bottom right BEV show the difference between the shift of the dose
and PG on the different CTs with respect to the initial CT1 used for planning. The spots
wih blue/red circles are the good/counter-indicated PBs boosted in the re-optimized TP.
(Tian et al. 2020)
higher than 99%, as it only failed in less than 20 cases among the entire tested 28286
PBs, while for the PBs with good PG-dose correlation the accuracy reached 100%. The
procedure of merging falloff 1 and falloff 2 (cf. section 5.3.2) was initially employed to
identify and correct for potential machine learning errors. It proved to work efficiently
when identifying PBs with the most preferred PG-dose correlation, since the coefficients
for identifying the PG-dose correlation of a given PB can be calculated by only one f1(x)
fitting and one f0(x) fitting, while other calculations are avoided.
More extensive computational resources are required for the MC simulation, especially
when the PG information is needed, as more protons are required for adequate statistics
for the PG emission signal in comparison to the dose. PG emissions were calculated with
high statistics (5 × 105 primary protons) for all the PBs of patient H&N1. Those data
were used for the construction of the machine learning model. For other patients, only
PBs of interest, i.e. PBs with maximum proton energy which have the Bragg peak inside
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Patient & PB ID ∆Dose
∆PG
(aggregation)
∆PG
(boost)
Mean ∆PG
(aggregation)
Mean ∆PG
(boost)
PROST1 field1 1 2.1 1.7 1.7 0.4 0.4
PROST1 field1 2 0.8 0.7 0.4 0.1 0.4
PROST1 field1 3 0.1 -0.5 -0.2 0.6 0.3
PROST1 field1 4 0.1 -0.4 -0.4 0.5 0.5
PROST1 field1 5 0.3 0.3 0.2 0.0 0.1
PROST1 field2 1 1.0 0.6 0.8 0.4 0.2
PROST1 field2 2 0.4 0.5 0.6 -0.1 -0.2
PROST1 field2 3 -0.5 -0.4 -0.4 -0.1 -0.1
PROST1 field2 4 -0.3 -0.6 -0.9 0.3 0.6
PROST1 field2 5 1.4 1.3 1.0 0.1 0.4
H&N4 field1 1 -1.2 -1.1 -1.2 -0.1 0.0
H&N4 field1 2 -1.3 -1 -0.7 -0.3 -0.6
H&N4 field1 3 -0.8 -0.7 -0.9 -0.1 0.1
H&N4 field1 4 -0.5 -0.4 -0.5 -0.1 0.0
H&N4 field1 5 -0.5 -0.5 -0.2 0.0 -0.3
Table 5.1: Comparison of the shift of the dose and PG laterally integrated profiles for
the good PBs on CT2 and CT1 for both patient cases. The shift of the dose, the ag-
gregated PG and the PG of the boosted central PB along with the shift difference be-
tween the dose and aggregated PG as well as PG of the boosted central PB are given by
∆Dose, ∆PG(aggregation), ∆PG(boost), ∆Shift(aggregation) and ∆Shift(boost), respec-
tively. The units are mm.
the PTV, were simulated with the same high statistics of 5 × 105 primary protons, while
other PBs were calculated using the statistics suggested by the CERR MC TPS handbook
(Resch et al. 2017), i.e. 1× 105 protons per PB, since PG emissions of those PBs are not
needed and only dose was scored. The machine learning model trained using the data of
patient H&N1 was tested on all the other patients (H&N2, H&N3, H&N4 and PROST1),
including head and neck as well as prostate cases, and was observed to have similar accu-
racy. This is because the machine learning model constructed in this work is trained using
data generated from comparably heterogeneous head and neck cases. Hence, there is no
need to train new models for a comparably homogeneous anatomy such as the prostate.
The study of (Xie et al. 2017), using a knife-edge slit collimator PG camera, reports that
the precision of PG signal depends on the proton statistics and a precision of 2 mm can
be achieved when the PB has 2 × 108 protons. Other researcher point out that proton
range shifts of 3 mm can be retrieved for a PB with 1 × 108 protons, using a 3D single
Compton camera (cf. section 3.1.1). In our study, a precision of 1 mm for the PG phsp
data profile is achieved when the proton statistics is boosted above at least 1.35 × 108.
This is consistent with the reported values from the literature. The setting of the wboost
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Patient & PB ID ∆Dose
∆PG
(aggregation)
∆PG
(boost)
Mean ∆PG
(aggregation)
Mean ∆PG
(boost)
PROST1 field1 1 -2.1 -1.7 -1.6 -0.4 -0.5
PROST1 field1 2 -3.0 -2.3 -3.0 -0.7 0.0
PROST1 field1 3 -4.0 -3.6 -3.5 -0.4 -0.5
PROST1 field1 4 -2.4 -2.4 -1.9 0.0 -0.5
PROST1 field1 5 -3.5 -2.8 -3.0 -0.7 -0.5
PROST1 field2 1 4.2 4.0 4.1 0.2 0.1
PROST1 field2 2 1.0 0.7 1.2 0.3 -0.2
PROST1 field2 3 -0.3 -0.2 0.5 -0.1 -0.8
PROST1 field2 4 -1.5 -0.5 -1.2 -1.0 -0.3
PROST1 field2 5 1.1 2.4 1.8 -1.3 -0.7
H&N4 field1 1 -3.0 -3.0 -3.2 0.0 0.2
H&N4 field1 2 -5.2 -4.8 -5.2 -0.4 0.0
H&N4 field1 3 -4.6 -4.6 -4.9 0.0 0.3
H&N4 field1 4 -4.2 -4.4 -4.3 0.2 0.1
H&N4 field1 5 -4.6 -4.4 -4.3 -0.2 -0.3
Table 5.2: Comparison of the shift of the dose and PG laterally integrated profiles for
the good PBs on CT3 and CT1 for both patient cases. The shift of the dose, the ag-
gregated PG and the PG of the boosted central PB along with the shift difference be-
tween the dose and aggregated PG as well as PG of the boosted central PB are given by
∆Dose, ∆PG(aggregation), ∆PG(boost), ∆Shift(aggregation) and ∆Shift(boost), respec-
tively. The units are mm.
is not arbitrary and a patient-specific tradeoff should be considered between the PG de-
tectability and TP quality. In this work, the boosting weights wboost were set to 1.35×108,
1.35 × 108, 1.35 × 108, 1.80 × 108 and 2.00 × 108 for four head and neck cancer and one
prostate patient, respectively. Those values were taken from the highest-statistics PBs in
the corresponding initial TPs. For future implementation a good tradeoff will be required
above the minimum PG detectability threshold for the available detector solutions and the
constraints that the chosen wboost should not spoil the TP optimization, e.g. by causing
hot spots.
The PB boosting approach has been compared to the PB aggregation method proposed
by (Xie et al. 2017). In the study on the influence of anatomical changes, both approaches
successfully predicted the dose shift using the PG shift for the PBs recommended by the
combined PG-dose correlation and dose surface indicators, while for the counter-indicated
PBs both approaches failed. However, the PBs recommended by the indicators introduced
in this work and boosted above the statistical threshold are more likely to provide reliable
PG information for proton range monitoring. Monitoring an arbitrary PB may not provide
correct proton range information. Moreover, the aggregated statistics is not always above
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Patient & PB ID ∆Dose
∆PG
(aggregation)
∆PG
(boost)
Mean ∆PG
(aggregation)
Mean ∆PG
(boost)
PROST1 field1 1 0.5 0.2 0.3 0.3 0.2
PROST1 field1 2 1.0 0.4 0.4 0.6 0.6
PROST1 field1 3 3.2 3.6 4.3 -0.4 -1.1
PROST1 field1 4 4.4 5.1 5.8 -0.7 -1.4
PROST1 field1 5 3.6 3.0 2.7 0.6 0.9
PROST1 field2 1 -0.2 -0.2 -0.6 0.0 0.4
PROST1 field2 2 5.1 2.5 9.1 2.6 -4.0
PROST1 field2 3 -0.8 1.4 0.6 -2.2 -1.4
PROST1 field2 4 -0.8 -1.4 -0.8 0.6 0.0
PROST1 field2 5 2.1 0.5 1.7 1.6 0.4
H&N4 field1 1 0.3 -1.2 -1.6 1.5 1.9
H&N4 field1 2 1.6 -2.6 -2.1 4.2 3.7
H&N4 field1 3 0.0 -1.0 -0.9 1.0 0.9
H&N4 field1 4 0.6 0.2 0.0 0.4 0.6
H&N4 field1 5 1.4 0.0 0.1 1.4 1.3
Table 5.3: Comparison of the shift of the dose and PG laterally integrated profiles for
the counter-indicated PBs on CT2 and CT1 for both patient cases. The shift of the
dose, the aggregated PG and the PG of the boosted central PB along with the shift
difference between the dose and aggregated PG as well as PG of the boosted central PB are
given by ∆Dose, ∆PG(aggregation), ∆PG(boost), ∆Shift(aggregation) and ∆Shift(boost),
respectively. The units are mm.
the PG detectability threshold while the statistics of the PBs is intrinsically guaranteed by
the PB boosting method. Furthermore, the central PB is not guaranteed to dominantly
contribute to the aggregation without special TP re-optimization. For instance, the third
counter-indicated PB used for one of the head and neck cancer patient, cf. table 5.3 and
5.4, has only 2.4× 106 protons while one of its aggregated nearby PB (more than 10 mm
away, with a Gaussian weight about 0.36) has 3.0 × 107 protons in the initial TP. In this
scenario the aggregated PG signal may reflect information more about that nearby PB
instead of the central one. Besides, the nearby PBs aggregated may have different proton
range due to the tissue heterogeneities (a distal surface difference of 14 mm has been ob-
served). These effects are not taken into account in the PBs aggregation approach. The
approach investigated in this thesis shows advantages in terms of guaranteed statistics,
reduced range mixing, improved lateral resolution and the contribution of the central PB.
In any case there is no conflict between those two approaches, as PG data of individual
PBs could still be aggregated regardless whether the central PBs are boosted or not. In
contrast, using the proposed approach to boost a few selected PBs could reduce the effects
mentioned above if the two approaches are combined.
Note that the dose surface indicator is introduced to quantify the effect of tissue hetero-
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Patient & PB ID ∆Dose
∆PG
(aggregation)
∆PG
(boost)
Mean ∆PG
(aggregation)
Mean ∆PG
(boost)
PROST1 field1 1 -2.8 -2.3 -1.9 -0.5 -0.9
PROST1 field1 2 -2.7 -1.9 -2.7 -0.8 0.0
PROST1 field1 3 -3.9 -4.7 -6.9 0.8 3.0
PROST1 field1 4 -15.6 -20.8 -20.8 5.2 5.2
PROST1 field1 5 -19.3 -25.1 -23.4 5.8 4.1
PROST1 field2 1 -0.4 -0.1 -0.2 -0.3 -0.2
PROST1 field2 2 -8.6 -3.9 -14.3 -4.7 5.7
PROST1 field2 3 -3.8 -10.4 -8.0 6.6 4.2
PROST1 field2 4 -0.8 -1.1 -1.0 0.3 0.2
PROST1 field2 5 -27.2 -26.5 -29.4 -0.7 2.2
H&N4 field1 1 -4.6 -3.5 -3.3 -1.1 -1.3
H&N4 field1 2 -5.8 -2.1 -2.0 -3.7 -3.8
H&N4 field1 3 -5.3 -7.2 -8.1 1.9 2.8
H&N4 field1 4 -2.6 -4.8 -3.9 2.2 1.3
H&N4 field1 5 -5.6 -3.5 -2.8 -2.1 -2.8
Table 5.4: Comparison of the shift of the dose and PG laterally integrated profiles for
the counter-indicated PBs on CT3 and CT1 for both patient cases. The shift of the
dose, the aggregated PG and the PG of the boosted central PB along with the shift
difference between the dose and aggregated PG as well as PG of the boosted central PB are
given by ∆Dose, ∆PG(aggregation), ∆PG(boost), ∆Shift(aggregation) and ∆Shift(boost),
respectively. The units are mm.
geneities and is mainly sensitive to the transversal tissue heterogeneities. It does not always
reject PBs delivered in heterogeneities. A large part of range uncertainties is caused by
systematic errors, e.g. in the CT-range calibration or by gross body surface and anatom-
ical changes. For those uncertainties, only a few PBs with good PG-dose correlation and
small dose surface std should be enough to give sufficient information whether the actual
irradiation scenario is consistent with the planning situation. For the PBs rejected by the
indicators, the shift of the PG is not guaranteed to match the shift of the dose accurately.
However, for most of the investigated PBs a large PG shift was typically observed when
the shift of the dose was large, and the difference between the shift of the dose and PG
was small. Hence, even for counter-indicated PBs, although the dose shift cannot be in-
ferred perfectly by the detected PG shift, PG monitoring could still be valuable to trigger
additional investigations, e.g. a new CT. The proposed indicators only provide the infor-
mation whether the dose shift of a given PB can be predicted accurately from the PG
shift or not. The user can choose and boost the PBs of interest, e.g. the good ones to
monitor more systematic range errors in regions of reduced transversal heterogeneities, or
the counter-indicated ones which are expected to be more sensitive to range uncertainties,
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Figure 5.28: The CT scans with superimposed MC dose distributions of a good and a
counter-indicated PB are shown on the left and right, respectively. The std values of the
CT numbers for A and B are 96 and 236, respectively. (Tian et al. 2020)
while maintaining the TP quality.
A safety ring of 5 mm was applied for the identification of the good PBs, i.e. only PBs sur-
rounded by small-dose-surface-std PBs were recommended, to prevent loss of robustness of
the PG-dose correlation from slight anatomical changes. However, the anatomical changes
are hard to predict. Though all PBs recommended in this work show small difference of the
shift between the dose and PG while the shift of the dose can reach 5.2 mm, the indicators
might still fail in the case of dramatic anatomical changes.
The PG signal for the work described in this chapter was obtained using the ideal emission
and phsp data calculated by Geant4, neglecting the response of a PG detection system
(cf. different solutions reviewed in chapter 3). A relevant study to address this aspect is
presented in chapter 6.
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Patient & PB ID (good)
Heterogeneities
(HU)
PB id (counter-indicated)
Heterogeneities
(HU)
PROST1 field1 1 50± 192 Prostate field1 1 38± 177
PROST1 field1 2 40± 186 Prostate field1 2 18± 96
PROST1 field1 3 29± 123 Prostate field1 3 48± 243
PROST1 field1 4 43± 137 Prostate field1 4 −3± 225
PROST1 field1 5 47± 130 Prostate field1 5 17± 197
PROST1 field2 1 25± 134 Prostate field2 1 29± 154
PROST1 field2 2 39± 181 Prostate field2 2 −26± 291
PROST1 field2 3 43± 151 Prostate field2 3 50± 199
PROST1 field2 4 23± 129 Prostate field2 4 40± 134
PROST1 field2 5 71± 237 Prostate field2 5 −26± 219
H&N4 field1 1 5± 140 H&N 1 −185± 432
H&N4 field1 2 28± 156 HH&N 2 −123± 326
H&N4 field1 3 0± 136 H&N 3 −26± 204
H&N4 field1 4 −34± 147 H&N 4 −47± 169
H&N4 field1 5 −32± 126 H&N 5 −40± 211
Table 5.5: Tissue heterogeneities in the beam path of the boosted good and counter-
indicated PBs (mean std value)
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Patient & PB ID ∆Range (mm) Naggregation Ncentral C
PROST1 field1 1 2.9 3.1×108 7.4×107 23.8%
PROST1 field1 2 2.6 1.9×108 1.4×107 7.3%
PROST1 field1 3 3.0 1.7×108 2.8×107 16.4%
PROST1 field1 4 3.8 4.0×108 4.7×107 11.8%
PROST1 field1 5 4.0 1.4×108 2.4×106 1.7%
PROST1 field2 1 1.4 1.9×108 4.6×107 24.2%
PROST1 field2 2 1.8 7.7×107 4.0×106 5.2%
PROST1 field2 3 4.3 2.6×108 4.1×107 15.8%
PROST1 field2 4 4.2 6.2×107 8.4×105 1.4%
PROST1 field2 5 5.3 1.3×108 7.8×106 6.0%
H&N4 field1 1 3.6 2.1×108 7.7×105 0.4%
H&N4 field1 2 4.1 2.4×108 2.1×107 8.9%
H&N4 field1 3 4.6 1.4×108 8.2×106 5.9%
H&N4 field1 4 3.9 1.3×108 1.1×106 0.9%
H&N4 field1 5 3.9 1.5×108 4.1×105 0.3%
Table 5.6: The range mixing and statistics of the PB aggregation for the selected good
PBs are shown. The range mixing, aggregated statistics, statistics of the central PB in the
initial TP and the corresponding contribution are given by ∆Range, Naggregation, Ncentral,
and C, respectively.
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Patient & PB ID ∆Range (mm) Naggregation Ncentral C
PROST1 field1 1 3.7 2.2×108 3.2×107 14.4%
PROST1 field1 2 3.0 4.0×107 2.7×106 6.6%
PROST1 field1 3 4.7 1.9×108 4.4×107 23.1%
PROST1 field1 4 5.0 1.2×108 9.1×107 76.2%
PROST1 field1 5 3.8 6.6×107 5.1×107 76.7%
PROST1 field2 1 3.4 1.5×108 5.1×106 3.4%
PROST1 field2 2 12.5 5.8×108 9.1×106 15.7%
PROST1 field2 3 1.7 9.1×107 4.5×106 5.0%
PROST1 field2 4 4.5 2.0×108 4.7×107 23.6%
PROST1 field2 5 7.0 1.4×108 3.2×106 2.3%
H&N4 field1 1 14.6 1.8×108 4.1×105 0.2%
H&N4 field1 2 10.8 1.2×108 3.1×105 0.3%
H&N4 field1 3 9.3 2.3×108 2.4×106 1.0%
H&N4 field1 4 7.8 2.3×108 1.4×106 0.6%
H&N4 field1 5 9.2 1.4×108 6.8×105 0.5%
Table 5.7: The range mixing and statistics of the PB aggregation for the selected counter-
indicated PBs are shown. The range mixing, aggregated statistics, statistics of the central
PB in the initial TP and the corresponding contribution are given by ∆Range, Naggregation,
Ncentral, and C, respectively.
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Chapter 6
TP re-optimization and PG
monitoring considering the response
of a knife-edge slit camera prototype
The work reported in the previous chapter focused on the correlation between the laterally
integrated depth profiles of dose and PG emission/phsp data simulated in Geant4, not
accounting for the response of a real PG camera. On the other hand, the computational
platform REGGUI (Janssens et al. 2009) provides the possibility to simulate the response
of the knife-edge PG camera prototype used in the first clinical PG application for PB
scanning conducted by (Xie et al. 2017). The relevant processes for simulation of dose,
PG emission and camera response in REGGUI were described in chapter 3. Since repro-
duction of such a detector response in the previously used Geant4 computational platform
would require access to confidential proprietary camera information, in this study REG-
GUI was used to investigate how the PG-dose correlation at emission (chapter 5) holds
at detection in presence of anatomical changes, taking into account a realistic PG system.
The re-optimization of the TP by boosting a few selected PBs above the set statistical
threshold while not spoiling the TP is discussed in chapter 5. This chapter focuses only
on the performance of the PB selection methods accounting for the camera response. The
statistics used is based on either the initial CERR TP (since REGGUI does not support
the function of treatment planning) or the preferred statistics of 2× 108 protons proposed
for PG monitoring by the previous study with this camera prototype (Xie et al. 2017).
Moreover, the PG signal detected by this type of system of limited field of view (FOV)
is affected by the relative position of the camera and the PG falloff. Hence, in this work,
an additional indicator is introduced based on the relative position of the detected PG
profile in the field of view (FOV) of the camera, as proposed by (Huang 2020). The PBs
used for the TPs of the same patients analyzed in section 5.4-5.5 are thus re-evaluated
using the PG-dose correlation, dose surface and camera position indicators, all based on
new REGGUI calculations. The combination of the PG-dose correlation and dose sur-
face indicators of chapter 5 is called PG emission indicator in the following. The shifts of
the laterally integrated depth profiles of dose, PG emission and PG detection generated
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by REGGUI simulation are compared to evaluate if the PBs, selected at emission, still
provide correct information for PG-based proton range verification when detected by a
real system. Although for each considered patient CTs at three different time points were
available, only the planning CT and the additional CT with larger anatomical changes are
used (called CT1 and CT2 in the following). Since the effect of boosting a few PBs on the
TP has been discussed in the previous investigations and would not change in the newly
proposed workflow, this chapter focuses only the reliability of the selected PBs in terms of
PG based proton range verification when including the detected signal. PB boosting and
PB aggregation are compared.
6.1 Comparison between the dose and PG emission
generated by Geant4 and REGGUI
The MC dose engine and the PG emission calculations used by REGGUI are based on
the MCsquare code and on the PG database generated by the MC PENH extension to
PENELOPE, respectively, which are both different from the Geant4 code (see chapter 4)
used in the previous chapter. Hence, the difference between the dose and PG emission
calculations of REGGUI and Geant4 has been investigated.
The 3D dose distribution as well as the laterally integrated depth dose and PG emission
profiles calculated by Geant4 and REGGUI are compared in figure 6.1 for a given PB
delivered near an air cavity in the pelvic region. The shift method as introduced in section
5.5 is employed to quantify the range difference of the profiles calculated by Geant4 and
REGGUI. The resulting range differences between profiles calculated by Geant4 and REG-
GUI are -4.0 mm and -8.6 mm for the dose and PG emission, respectively. The histograms
of the dose range difference for all the PBs of interest for the head and neck and prostate
patient cases are shown in figure 6.2. A systematic range difference is observed for patient
PROST1, due to a comparably longer proton range in Geant4. The PB identification by
the PG emission indicators using the different datasets is compared in figure 6.3. The gen-
eral area of good/counter-indicated PBs are similar. Differences of PBs identifications are
mainly observed near the boundary of the recommended and rejected areas. To maintain
the data consistency for the investigations presented in this chapter, besides the parame-
ters used for PBs selection that are the same as those used in chapter 5 (based on Geant4),
all the data used in the following are generated using REGGUI.
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Figure 6.1: The axial slice of the 3D dose distribution in colourwash superimposed onto
the grayscale CT (top) as well as laterally integrated depth dose (bottom left) and PG
(bottom right) profiles of a PB passing through tissue heterogeneities, as calculated by
Geant4 (top: left panel; bottom: red lines) and REGGUI (top: right panel; bottom: blue
lines).
6.2 Accounting for camera position
6.2.1 Camera position indicator
Highest-energy candidate PBs with the Bragg peak in the safe region inside the PTV (cf.
section 5.3.3) are simulated on CT1 using REGGUI. By giving the camera position with
respect to the PTV isocenter, the PG detection profiles consisting of 20 data points, which
correspond to the PG counting of 20 detectors (each of 4 mm length) of the camera, are
obtained. The profiles are firstly normalized in the region of 17-63 mm (where 0 is the
beginning of the first detector) and then smoothed with a Savitzky-Golay filter. The PG
profile falloff is defined by the distal region from 90% to 10% of the maximum value. PBs
with falloffs which fulfill the following criteria, which were defined based on the analysis
of a large number of simulated and measured data by (Huang 2020), are identified to be
centered at the camera FOV (see example in figure 6.4):
1. The length of the falloff is longer than 8 mm
2. The falloff is within the region of 18 to 62 mm
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Figure 6.2: Histograms of the proton range differences between the individual PB dose
distributions calculated by Geant4 and REGGUI on CT1 for the patients considered in
this chapter.
3. The center (50% point) of the falloff is within 36 to 44 mm
Candidate PBs have generally a different range depending on the shape of the PTV, thus
not all PBs are necessarily centered in the FOV of the camera at a given position, depend-
ing on the position of the camera set by the user. In this work, the camera positions are
set to those values where the number of centered PBs is maximized, i.e. 6.25, 9.5 and 48.5
mm away from the PTV isocenter for the TP field of patient H&N4, as well as field 1 and
field 2 of patient PROST1, respectively.
6.2.2 Shift calculation
The spot-by-spot shift of the dose, PG emission and PG detection laterally integrated
depth profiles on different CTs are compared to evaluate the reliabilities of the selected
PBs in terms of proton range verification. The shifts of the dose and PG emission and
detection profiles are calculated by applying the same shift algorithm described in chapter
5 on the REGGUI-generated data on the corresponding CTs.
The PG detection profile calculated by REGGUI is the expectation of the PG counting
numbers per incident proton in the corresponding camera detectors (called PG simulation
in the following), not accounting for the underlying Poisson statistics. To obtain the real-
istic camera response, the PG simulation profile is firstly multiplied by the PB statistics
and converted to integers randomly, e.g. a PG counting of 3.6 is converted to 3 by 40%
chance or 4 by 60% chance. This is in the following referred to as PG simulation. A Pois-
son noise is then added to the counting numbers, thus the camera in-silico measurement
profile, hereafter referred to as measurement, is obtained (figure 6.5). In case of emulation
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Figure 6.3: PB classification based on the PG emission indicator using Geant4 (top) and
REGGUI (bottom) data. The blue and red spots are directly recommended and rejected
by the indicator, respectively. The black spots are initially recommended but then rejected
when accounting for the safety margin of 5 mm for the dose surface indicator (see section
5.5.4).
of measurements, the aggregation profiles are created by summing up the noisy profiles of
relevant PBs using a Gaussian weight, as explained in section 5.2.
The following scenarios are evaluated:
1. Camera response ideal scenario: In this scenario, the shifts difference be-
tween dose and PG simulation profiles on different CTs are compared to the
shift difference between dose and PG emission to investigate the effect of cam-
era response regardless of statistical noise considerations.
2. Camera response realistic scenario for the comparison between measurement
and simulation: 1000 generated PG measurement profiles with Poisson noise on
CT2 are compared to the ideal PG simulation profiles on CT1, corresponding
to a realistic monitoring workflow which compares the detected PG signal on
the daily anatomy to the expected PG simulation on the anatomy from the
treatment plan for proton range verification (accuracy check).
3. Camera response realistic scenario for the comparison between measurement
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Figure 6.4: The camera position indicator is applied on an exemplary PG detection profile
(blue and red). The red line is the falloff region. The 90%, middle (50%) and 10% points
are marked by arrows.
and measurement: Shifts of 1000 pairs of PG measurement profiles on different
CTs are compared to the dose shifts, corresponding to a realistic monitoring
workflow, which compares the detected PG signals at different treatment time
points for proton range verification (reproducibility check).
To explore the effects of the counting statistics depending on the amount of primary pro-
tons per PB, two scenarios are used:
1. Statistics from the initial CERR TP.
2. Ideal statistics of 2.0× 108 protons for each PB as suggested by the work of
(Xie et al. 2017), to evaluate the implications of the PB boosting method.
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Figure 6.5: The REGGUI output (readout of the 20 detectors of the camera before ran-
dom rounding), PG simulation profile with random rounding and PG measurement profile
accounting for the Poisson noise. The statistics of the left and right profiles are 2.5× 106
and 6.8× 107, respectively. The PB statistics used is from the initial TP.
6.3 Results
6.3.1 Effect of PB statistics on the shift detection precision
The maximum PG counts per detector bin generated by the REGGUI simulation are less
than 2.1×10−6 and 1.7×10−6 PG/protons for the patient H&N4 and PROST1, respectively.
PBs need more than 5.9× 105 protons to generate at least 1 PG counting in the camera.
A profile with low statistics, e.g. around 5.9 × 105, would consist of a series of small
numbers, e.g. 0, 1, 2, 3 etc., and a falloff cannot be identified (see figure 6.5 left, green
profile). Comparing 1000 generated PG measurement profiles and the corresponding PG
simulation profile, the change of the std value of the shifts following the change of statistics
is shown in figure 6.6. A precision of 1.2 mm (1 std) can be achieved when the PB has
more than 1× 108 protons.
6.3.2 Camera response ideal scenario (simulation vs simulation)
In this scenario, the effect of statistical noise is not considered since all signals in this sec-
tion are deterministic besides the explained random rounding process. The spot-by-spot
shifts of the profiles of the dose, PG emission and PG simulation on CT2 with respect
to CT1 are compared in figure 6.7 in BEV. Here, colour coding reflects the shift in mm
and circles distinguish the identification of the indicators for spot selection: spots with
black circles are those recommended by both emission and camera indicators; spots with
red/blue circles are those recommended by only the camera/PG emission indicator, respec-
tively; spots without circles are those rejected by both indicators.
The shift differences between the dose and PG emission of most (118/125) PBs recom-
mended by the PG emission indicator are lower than 1.5 mm with a mean value of 0.6 mm
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Figure 6.6: Standard deviation of the shifts between PG measurement profiles and the
corresponding PG simulation profiles under different PB statistics. Note that PG mea-
surement profiles below 5.9 × 105 may be invalid due to low PG counting as explained in
figure 6.5 and the text.
and a std of 0.9 mm. The 7 failure cases, exhibiting maximum deviation of 3.8 mm, are
distributed at the edge of the recommended area.
For the PG simulation, there are 21 PBs that are recommended by the PG emission in-
dicator but have shift differences higher than 1.5 mm. Applying the camera indicator, 10
of those failure cases are rejected because they are not centered at the camera FOV. Only
2 spots of the remaining 11 PBs have shift difference values higher than 2 mm, with a
maximum value of 4.5 mm. These two spots are among the above mentioned 7 failure
cases of PG emission indicator (an example has been shown in the figure 6.8).
To compare the methods of PB boosting and PB aggregation (with a sigma of 7 mm, see
section 5.2) at the detection level, three PBs are selected among the PBs which are (1)
recommended by both indicators, (2) recommended only by the PG emission indicator, (3)
recommended only by the camera indicator, (4) rejected by all indicators (see figure 6.9).
The results are shown in table 6.1. For the PBs recommended by both indicators, the
maximum shift difference values are 1.6 mm (aggregation) and 1.4 mm (boosting) with
mean values of 0.8 mm (aggregation) and 0.5 mm (boosting) along with std of 0.7 mm
(aggregation) and 0.6 mm (boosting). For the PBs recommended by only the PG emis-
sion indicator, the maximum shift differences are -1.9 mm (aggregation) mm and 3.8 mm
(boosting) with mean values of 1.0 mm (both) along with std of 1.0 mm (aggregation) mm
and 1.6 mm (boosting). For the PBs recommended by only the camera indicator, the max-
imum shift differences are -5.6 mm (aggregation) and 5.1 mm (boosting) with mean values
of 1.0 mm (aggregation) and 1.1 mm (boosting) along with std of 2.8 mm (aggregation)
mm and 2.6 mm (boosting). For the PBs rejected by all the indicators, the maximum
shift differences are 13.2 mm (aggregation) and 9.1 (boosting) with mean values of 1.4 mm
(aggregation) and 0.6 mm (boosting) along with std of 4.7 mm (aggregation) mm and 4.5
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Figure 6.7: The shift differences between dose and PG emission are shown on the top
and the shift differences between dose and PG simulation of the ideal detected signal are
shown on the bottom for the three considered fields (left to right). The shift difference is
color coded. PBs with black circles are recommended by both PG emission and camera
indicators. PBs with red circles are recommended only by the camera indicator, while PBs
with blue circles are recommended only by the PG emission indicator.
mm (boosting).
6.3.3 Camera response scenario of comparing the measurement
on CT2 to the simulation on CT1
The shifts between the generated 1000 PG measurement profiles on CT2 and the corre-
sponding PG simulation profiles on CT1 are compared to the shifts of the dose profiles
on different CTs. The results, quantified as the mean and std of the shift differences, are
shown in the middle and bottom rows in figure 6.10 using statistics from the initial CERR
TP and boosted statistics, respectively. And the ground truth, i.e. shift difference using
the PG simulation profiles, is given on the top as reference. The shift differences calculated
using the high statistics scenario approach the ground truth with a mean deviation of 0.2
mm for all PBs. The deviations of all PBs recommended by both indicators are lower
than 2 mm. Most of the PBs in the initial TP do not have enough protons for valid PG
detection.
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Figure 6.8: The magnitude of the change of the air cavity near the beam path of this PB
is bigger than the safe margin set for the indicators (cf. section 5.5.3), leading to a failure
of the PG emission indicator. The position of this PB in BEV and the axial slice of the
3D dose distribution on both CTs are shown on the top right and left, respectively. The
shifts of the dose (bottom left), PG emission (bottom middle) and PG detection (bottom
right) are 3.4, 7.2, and 4.8 mm, respectively.
Comparisons between PB boosting and PB aggregation approaches for the selected PBs
are shown in table 6.2 (only statistical uncertainty is reported not accounting for uncer-
tainty caused by e.g. the shifting step size, cf. section 5.5.1.). For the PBs recommended
by both indicators, the maximum shift differences are 2.4 mm (aggregation) and 1.8 mm
(boosting) with mean values of 1.3 mm (aggregation) and 0.8 mm (boosting) along with
std of 1.0 mm (both). For the PBs recommended by only the PG emission indicator, the
maximum shift differences are 2.7 mm (aggregation) mm and 3.9 mm (boosting) with mean
values of 1.2 mm (aggregation) and 1.5 mm (boosting) along with std of 1.6 mm (both).
For the PBs recommended by only the camera indicator, the maximum shift differences
are 5.3 mm (aggregation) and 5.9 mm (boosting) with mean values of 2.0 mm (both) along
with std of 2.2 mm (aggregation) and 2.3 mm (boosting). For the PBs rejected by the
indicators, the maximum shift differences are 14.8 mm (aggregation) and 11.8 (boosting)
with mean values of 3.5 mm (aggregation) and 3.2 mm (boosting) along with std of 5.0
mm (aggregation) and 4.3 mm (boosting).
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Figure 6.9: Figures on the top show the color coded dose shifts of the PBs investigated
in this work, with circles referring to the PBs selected for the comparison between PB
boosting and PB aggregation (see text). The positions are shown on the bottom. The
spots with black, blue and red circles are those recommended by both indicators, only
PG emission indicator and only camera indicators, respectively. PBs rejected by both
indicators are with green circles.
6.3.4 Camera response scenario of comparing the PG measure-
ments on different CTs
The shifts between the generated 1000 pairs of PG measurement on different CTs are
compared to the shifts of the dose profiles on different CTs (figure 6.11). The results
are shown in the middle and bottom rows using statistics from the initial CERR TP and
boosted statistics, respectively. The shift differences using PG simulation profiles are shown
on the top as ground truth. The shift differences calculated using high statistics approach
the ground truth with a mean deviation of -1.3 mm for all PBs. The deviations of all PBs
recommended by both indicators are lower than 2 mm. Most of the PBs in the initial TP
do not have enough protons for valid PG detection.
Table 6.3 compares the PB boosting and PB aggregation approaches for the selected PBs
in terms of the shift difference between dose and PG. Only statistical uncertainty is shown
as mentioned above. For the PBs recommended by both indicators, the maximum shift
differences are 2.4 mm (aggregation) and 2.0 mm (boosting) with mean values of 1.3 mm
(aggregation) and 0.9 mm (boosting) along with std of 1.0 mm (aggregation) and 0.9 mm
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Figure 6.10: The shift differences between dose and PG simulation are shown on the top.
The shift differences between dose and PG measurement (measurement vs. simulation)
using the initial TP statistics and the boosted statistics are shown in the middle and
bottom, respectively. The mean shift difference is color coded and the spot size indicates
the std of the shift values, i.e. bigger spots have smaller std. PBs with black circles are
those recommended by both PG emission and camera indicators. PBs with red circles are
recommended by only the camera indicator and PBs with blue circles are recommended
by only the PG emission indicator.
(boosting). For the PBs recommended by only the PG emission indicator, the maximum
shift differences are 2.6 mm (aggregation) mm and 4.1 mm (boosting) with mean values of
1.4 mm (aggregation) and 1.6 mm (boosting) along with std of 1.5 mm (aggregation) and
1.8 mm (boosting). For the PBs recommended by only the camera indicator, the maximum
shift differences are 6.1 mm (aggregation) and 5.7 mm (boosting) with mean values of 2.3
mm (both) along with std of 2.4 mm (aggregation) and 2.2 mm (boosting). For the PBs
rejected by the indicators, the maximum shift differences are 15.8 mm (aggregation) and
11.8 (boosting) with mean values of 3.6 mm (aggregation) and 3.3 mm (boosting) along
with std of 5.0 mm (aggregation) and 4.1 mm (boosting).
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Figure 6.11: The shift differences between dose and PG simulation are shown on the top.
The shift differences between dose and PG measurement (measurement vs. measurement)
using the initial TP statistics and the boosted statistics are shown in the middle and
bottom, respectively. The mean shift difference is color coded and the spot size indicates
the std of the shift values, i.e. bigger spots have smaller std. PBs with black circles are
those recommended by both PG emission and camera indicators. PBs with red circles are
recommended by only the camera indicator and PBs with blue circles are recommended
by only the PG emission indicator.
6.3.5 Statistics comparison between the PB aggregation and PB
boosting
The statistics, range mixing and contribution of the central beam to the aggregated PBs
(see section 5.7) are shown in the table 6.4. Statistics of 11 aggregated PBs are observed to
be lower than 1×108. Two of them (prostate field2 PB 1 and 2) are recommended by both
indicators and have higher PG shift error (1.6 mm for the comparison between measure-
ment and simulation and more than 2.3 mm for the comparison between measurements on
different CTs) than other recommended PBs (cf. table 6.2 and 6.3). The maximum range
mixing observed is 12.1 mm, and the general contribution of the central PBs is low (with a
maximum value of 57.1%). These results are consistent to the previous findings in section
5.7 though different PBs are selected.
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6.4 Discussion
In this chapter, an indicator proposed by (Huang 2020) accounting for the effect of the
relative position of the detector to the PG falloff is investigated for a knife-edge PG camera
of limited FOV, which has been already deployed clinically by (Xie et al. 2017, Richter
et al. 2016). PBs whose PG emission profile are supposed to reflect correct dose informa-
tion but cannot be detected correctly by the camera are identified and rejected by the new
indicator, which thus augments the work of chapter 5 to account for a realistic PG detec-
tor. Moreover, the influence of the camera response on the proposed boosting approach
in comparison to the initial TP for a reliable range monitoring representative of the dose
delivery is investigated for different PG detection scenarios under the different underly-
ing statistics. Comparisons between the PB boosting and the alternative PB aggregation
methods are also presented.
The PBs of interest for selection in this study, according to the method highlighted in chap-
ter 5, are the maximum energy PBs which have their Bragg peaks inside the safe region
in the PTV. The ranges of those PBs are varying, depending on the shape of the PTV.
Thus, only some of the PBs of interest have their PG falloff centered in the FOV of the
camera for a given camera position. In this work, the camera is set to the position where
the number of the centered PBs is maximized. Another option could be to set candidate
PBs for boosting to those which have their PG falloffs at the same depth, depending on
the users interest.
For the investigated clinical cases of a head and neck and prostate cancer patient, the
initial TPs do not provide sufficient statistics for most of the PBs to generate enough PG
detection signal. The simulation based on the REGGUI platform shows that a precision of
0.8 mm can be achieved when PBs have more than 2× 108 protons for the considered PG
camera. This is consistent to previous studies with the same computational platform (Xie
et al. 2017) or Geant4 for an ideal detector (Tian et al. 2018). All investigated scenarios
of emulated measurement at a certain day versus the simulation on the planning CT and
the comparison between emulated measurements at different fractions show that the infor-
mation provided by the emulated PG measurement approaches the ground truth, i.e. the
simulated PG detected signal without noise, with increasing statistical weight (i.e., number
of protons) of the PBs. Besides, the general precision of the scenario of emulated measure-
ment vs. simulation is observed to be better than that of measurement vs. measurement,
as the result of the Poisson noise introduced in the measurement at the first time point.
This thus supports the currently mostly implemented PG monitoring approach, comparing
a given daily measurement to the prediction obtained on the basis of the treatment plan,
provided that a reliable calculation engine is used for such a prediction.
The maximum shift difference between dose and PG on different CTs observed in ideal
cases (simulation vs. simulation) for the PBs recommended by both the emission indi-
cators of chapter 5 and the new camera position indicator are 1.9 mm and 1.5 mm for
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PB aggregation and PB boosting with mean values of 0.8 mm and 0.5 mm, respectively.
Both approaches are comparable. However, PB aggregation does not guarantee enough
statistics for the aggregated PBs. In this work, the minimum aggregation statistics is
3.6× 107 and there are 11 PBs that have less than 1.0× 108 protons among the 24 selected
PBs including 2 PBs recommended by both indicators. These two PBs have larger PG
shift errors (1.6 mm for the comparison between measurement and simulation and more
than 2.3 mm for the comparison between measurements on different CTs), compared to
other recommended PBs, leading to a higher uncertainty in proton range verification. As
demonstrated in previous chapters, the PB boosting approach shows advantages in terms
of guaranteed statistics, range mixing, lateral resolution and the contribution of the central
PB but there is no conflict between those two approaches.
PBs recommended by only the camera indicator are centered in the FOV of the camera.
Although these PBs are not recommended by the PG emission indicator, their PG signal
can still correctly reflect the PG emission. Thus, these PBs can still provide valid informa-
tion to trigger additional investigations, e.g. a new CT as discussed in chapter 5. For PBs
rejected by the camera indicator, their PG detection signals are not well correlated with
the corresponding PG emission and cannot be used for proton range verification, regardless
whether they are recommended by the PG emission indicator or not.
Failure cases of the PG emission indicator are observed for a few recommended PBs that
exhibit large (up to 3.8 mm) shift difference between the dose and PG emission. These
PBs are distributed at the edge of the recommended PB area. A safety ring of 5 mm (cf.
section 5.5.4) is applied for the PG emission indicator. For larger anatomical changes, the
indicator might fail. Besides, the PG emission indicator is developed based on the dataset
generated by Geant4. The profiles generated by REGGUI are slightly different from those
generated by Geant4. This causes different PB identification as shown in figure 6.3. A re-
finement of the algorithm or machine learning model trained using PG detection/emission
generated by REGGUI simulation of experimental data could be helpful to further improve
this process. The camera indicator could also fail due to large anatomical changes, e.g. the
Bragg peak is at the center of FOV on CT1 but moves outside of the camera FOV on CT2
due to anatomical changes. In this case, a large PG shift can be observed. Although PG
detection data is available in this work, the PG dose correlation is still quantified using PG
emission. On the one hand, PG emission provides more explicit information of the effect
of tissue heterogeneity, which is an important source of the mismatching between PG and
dose, not losing information due to the PG transport in tissue until eventual detection.
On the other hand, the PG emission information is independent of the camera type and
needs less computational resources, compared to those needed for the other camera-free
phsp data (see section 5.1), thus providing the feasibility to be combined with other camera
specific indicators.
Besides few exceptions which could be overcome in the future by e.g. fine tuning of the
algorithm for camera specific PG signal, avoidance of PBs in the edge areas and better
safety margin setting, it could be generally shown that the proposed boosting approach
with emission selection criteria complemented by the camera position can still work, i.e.,
provide a more reliable PG monitoring than for the initial TP plan, when evaluated at
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Patient & PB ID ∆Dose
∆PG
(aggregation)
∆Shift
(aggregation)
∆PG
(boost)
∆Shift
(boost)
PB recommended by both indicators
H&N4 field1 1 3.7 2.1 1.6 3.1 0.6
H&N4 field1 2 4.4 2.9 1.5 3.0 1.4
H&N4 field1 3 4.9 3.9 1.0 4.8 0.1
PROST1 field1 1 2.6 2.0 0.6 2.1 0.5
PROST1 field1 2 3.3 1.9 1.4 2.1 1.3
PROST1 field1 3 4.0 3.0 1.0 3.3 0.8
PROST1 field2 1 -2.1 -1.9 -0.2 -1.8 -0.3
PROST1 field2 2 -0.4 -1.0 0.6 -0.8 0.4
PROST1 field2 3 1.8 2.1 -0.2 2.1 -0.3
PB recommended by only PG emission indicators
H&N4 field1 1 4.7 3.0 1.7 4.0 0.7
H&N4 field1 2 5.1 3.9 1.2 3.0 2.1
H&N4 field1 3 4.9 3.1 1.9 1.1 3.8
PROST1 field1 1 3.6 1.8 1.8 1.5 2.0
PROST1 field1 2 4.4 3.2 1.1 3.0 1.4
PROST1 field1 3 2.7 1.2 1.5 2.6 0.1
PROST1 field2 1 -4.6 -3.1 -1.4 -2.9 -1.7
PROST1 field2 2 2.0 0.4 1.6 1.1 0.9
PROST1 field2 3 1.4 1.1 0.3 1.5 -0.1
PB recommended by only camera indicator
H&N4 field1 1 3.3 2.1 1.1 2.1 1.2
H&N4 field1 2 3.4 2.0 1.4 1.1 2.3
H&N4 field1 3 7.0 2.8 4.3 3.0 4.1
PROST1 field1 1 1.9 0.8 1.1 0.4 1.5
PROST1 field1 2 2.4 -3.2 5.6 -2.7 5.1
PROST1 field1 3 5.9 9.4 -3.6 9.3 -3.5
PROST1 field2 1 26.1 27.7 -1.6 27.4 -1.4
PROST1 field2 2 -1.5 -1.4 -0.0 -1.4 -0.0
PROST1 field2 3 0.4 0.1 0.3 0.2 0.3
PB rejected by both indicators
H&N4 field1 1 8.2 11.4 -3.2 14.2 -6.0
H&N4 field1 2 5.6 5.2 0.4 7.5 -1.9
H&N4 field1 3 2.9 3.8 -0.8 -3.0 6.0
PROST1 field1 1 2.4 1.1 1.3 1.7 0.7
PROST1 field1 2 11.3 11.6 -0.4 13.4 -2.1
PROST1 field1 3 23.6 21.7 1.9 23.3 0.3
PROST1 field2 1 18.9 5.7 13.2 9.8 9.1
PROST1 field2 2 1.8 1.9 -0.1 2.8 -1.0
PROST1 field2 3 1.0 0.7 0.3 0.6 0.4
Table 6.1: Comparison between the shifts of the dose (∆Dose) and ideal detected PG
profiles (∆PG for simulation vs. simulation) on different CTs for PB aggregation and
boosting approaches (see location of selected spots in figure 6.9). The unit for the following
values are mm. The worst shift difference in each cases are highlighted in red.
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Patient & PB ID ∆Dose
∆PG
(aggregation)
Mean ∆shift
(aggregation)
∆PG
(boost)
Mean ∆shift
(boost)
PB recommended by both indicators
H&N4 field1 1 3.7 1.7± 0.7 2.1 2.6± 0.9 1.1
H&N4 field1 2 4.4 2.2± 0.9 2.2 2.6± 0.9 1.8
H&N4 field1 3 4.9 2.5± 1.0 2.4 3.1± 1.0 1.8
PROST1 field1 1 2.6 1.6± 1.1 1.0 1.6± 1.5 1.0
PROST1 field1 2 3.3 1.3± 1.2 2.0 1.7± 1.5 1.7
PROST1 field1 3 4.0 2.3± 1.5 1.7 3.2± 1.6 0.8
PROST1 field2 1 -2.1 −1.5± 1.6 -0.6 −1.0± 1.3 -1.2
PROST1 field2 2 -0.4 −0.9± 1.6 0.5 −0.3± 1.3 -0.1
PROST1 field2 3 1.8 1.5± 1.4 0.3 1.7± 1.5 0.1
PB recommended by only PG emission indicators
H&N4 field1 1 4.7 2.1± 0.7 2.6 2.9± 1.1 1.9
H&N4 field1 2 5.1 2.4± 0.9 2.7 2.2± 1.0 2.8
H&N4 field1 3 4.9 2.6± 0.8 2.3 1.1± 0.9 3.9
PROST1 field1 1 3.6 2.2± 1.9 1.3 1.7± 1.5 1.8
PROST1 field1 2 4.4 2.6± 1.4 1.8 2.1± 1.5 2.2
PROST1 field1 3 2.7 1.5± 1.3 1.2 1.6± 1.4 1.1
PROST1 field2 1 -4.6 −2.2± 1.6 -2.4 −2.6± 1.4 -2.0
PROST1 field2 2 2.0 1.1± 1.9 0.9 0.9± 1.6 1.1
PROST1 field2 3 1.4 1.1± 1.8 0.3 0.8± 1.6 0.6
PB recommended by only camera indicator
H&N4 field1 1 3.3 1.8± 0.6 1.4 1.7± 0.9 1.6
H&N4 field1 2 3.4 1.5± 0.7 1.9 1.1± 0.8 2.3
H&N4 field1 3 7.0 1.7± 1.2 5.3 2.3± 1.1 4.7
PROST1 field1 1 1.9 0.5± 2.1 1.4 0.9± 2.2 1.0
PROST1 field1 2 2.4 −2.0± 3.9 4.4 −1.9± 3.3 4.3
PROST1 field1 3 5.9 5.8± 4.6 0.0 6.0± 6.3 -0.1
PROST1 field2 1 26.1 20.7± 2.9 5.3 20.2± 2.0 5.9
PROST1 field2 2 -1.5 −1.4± 1.7 -0.0 −1.2± 2.0 -0.3
PROST1 field2 3 0.4 0.4± 2.3 0.0 −0.1± 1.6 0.5
PB rejected by both indicators
H&N4 field1 1 8.2 5.3± 1.0 2.9 7.6± 0.9 0.6
H&N4 field1 2 5.6 3.3± 1.3 2.3 4.7± 1.2 0.9
H&N4 field1 3 2.9 2.6± 0.9 0.4 −2.3± 0.9 5.2
PROST1 field1 1 2.4 0.7± 2.1 1.7 0.9± 1.5 1.5
PROST1 field1 2 11.3 10.8± 6.1 0.4 11.4± 5.2 -0.1
PROST1 field1 3 23.6 15.0± 4.9 8.6 15.4± 8.0 8.2
PROST1 field2 1 18.9 4.1± 3.5 14.8 7.1± 3.9 11.8
PROST1 field2 2 1.8 1.6± 1.5 0.2 1.7± 2.1 0.1
PROST1 field2 3 1.0 0.9± 1.8 0.1 0.5± 1.6 0.5
Table 6.2: Comparison between the shifts of the dose (∆Dose) and PG detection profiles
(∆PG for measurement vs. simulation) on different CTs for PB aggregation and boosting
approaches (see location of selected spots in figure 6.9). The unit for the following values
are mm. The worst shift difference in each cases are highlighted in red.
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Patient & PB ID ∆Dose
∆PG
(aggregation)
Mean ∆shift
(aggregation)
∆PG
(boost)
Mean ∆shift
(boost)
PB recommended by both indicators
H&N4 field1 1 3.7 1.9± 0.9 1.8 2.7± 1.3 1.1
H&N4 field1 2 4.4 2.1± 1.2 2.2 2.4± 1.3 2.0
H&N4 field1 3 4.9 2.5± 1.3 2.4 3.3± 1.5 1.6
PROST1 field1 1 2.6 1.6± 1.6 1.1 1.4± 2.1 1.2
PROST1 field1 2 3.3 1.5± 1.7 1.9 1.6± 2.2 1.7
PROST1 field1 3 4.0 2.1± 2.1 1.9 2.9± 2.4 1.2
PROST1 field2 1 -2.1 −1.4± 2.4 -0.7 −1.2± 2.0 -1.0
PROST1 field2 2 -0.4 −0.8± 2.3 0.4 −0.4± 1.9 0.1
PROST1 field2 3 1.8 1.4± 2.0 0.5 1.5± 2.2 0.4
PB recommended by only PG emission indicators
H&N4 field1 1 4.7 2.3± 1.0 2.4 2.8± 1.6 2.0
H&N4 field1 2 5.1 2.5± 1.3 2.6 2.0± 1.5 3.0
H&N4 field1 3 4.9 2.3± 1.2 2.6 0.8± 1.4 4.1
PROST1 field1 1 3.6 1.2± 2.8 2.4 1.1± 2.0 2.5
PROST1 field1 2 4.4 2.7± 2.1 1.7 2.1± 2.1 2.3
PROST1 field1 3 2.7 1.4± 1.9 1.3 1.6± 2.0 1.1
PROST1 field2 1 -4.6 −2.5± 2.2 -2.1 −2.3± 2.0 -2.2
PROST1 field2 2 2.0 0.6± 2.6 1.4 0.9± 2.3 1.1
PROST1 field2 3 1.4 0.7± 2.8 0.7 0.7± 2.3 0.7
PB recommended by only camera indicator
H&N4 field1 1 3.3 1.8± 0.9 1.4 1.7± 1.3 1.6
H&N4 field1 2 3.4 1.6± 1.0 1.8 1.2± 1.2 2.2
H&N4 field1 3 7.0 1.8± 1.8 5.3 2.2± 1.6 4.8
PROST1 field1 1 1.9 0.1± 3.1 1.8 0.2± 3.5 1.7
PROST1 field1 2 2.4 −2.3± 5.4 4.7 −2.0± 4.6 4.4
PROST1 field1 3 5.9 6.2± 5.4 -0.4 5.7± 7.1 0.2
PROST1 field2 1 26.1 20.0± 4.7 6.1 20.3± 3.0 5.7
PROST1 field2 2 -1.5 −1.7± 2.5 0.2 −1.3± 2.9 -0.2
PROST1 field2 3 0.4 0.3± 3.3 0.2 0.1± 2.2 0.4
PB rejected by both indicators
H&N4 field1 1 8.2 5.2± 1.5 3.0 7.5± 1.3 0.7
H&N4 field1 2 5.6 3.3± 1.8 2.3 4.6± 1.9 1.0
H&N4 field1 3 2.9 2.5± 1.3 0.4 −2.2± 1.5 5.2
PROST1 field1 1 2.4 0.9± 3.1 1.5 1.0± 2.2 1.4
PROST1 field1 2 11.3 10.9± 6.9 0.4 10.8± 6.2 0.5
PROST1 field1 3 23.6 15.4± 5.4 8.3 15.9± 8.1 7.7
PROST1 field2 1 18.9 3.7± 4.7 15.2 7.1± 4.7 11.8
PROST1 field2 2 1.8 1.3± 2.4 0.5 1.5± 3.1 0.3
PROST1 field2 3 1.0 0.2± 2.7 0.8 −0.1± 2.4 1.1
Table 6.3: Comparison between the shifts of the dose (∆Dose) and PG detection profiles
(∆PG for measurement vs. measurement) on different CTs for PB aggregation and boost-
ing approaches (see location of selected spots in figure 6.9). The unit for the following
values are mm. The worst shift difference in each cases are highlighted in red.
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Patient & PB ID ∆Range (mm) Naggregation Ncentral C
PB recommended by both indicators
H&N4 field1 1 6.5 2.2×108 2.0×107 8.9%
H&N4 field1 2 4.6 1.3×108 1.3×107 10.2%
H&N4 field1 3 4.6 1.5×108 4.1×105 0.3%
PROST1 field1 1 0.8 2.7×108 2.4×106 0.9%
PROST1 field1 2 3.3 2.0×108 4.3×107 21.1%
PROST1 field1 3 2.8 1.3×108 5.3×106 3.9%
PROST1 field2 1 0.6 7.6×107 2.2×107 2.9%
PROST1 field2 2 1.4 8.5×107 2.0×106 23.6%
PROST1 field2 3 3.4 1.3×108 1.2×107 0.9%
PBs recommended by only PG emission indicators
H&N4 field1 1 2.9 3.0×108 3.4×106 1.1%
H&N4 field1 2 2.5 1.9×108 1.1×107 5.8%
H&N4 field1 3 2.5 1.9×108 8.4×105 0.4%
PROST1 field1 1 1.0 4.2×107 2.5×106 6.0%
PROST1 field1 2 1.8 1.7×108 2.5×107 14.7%
PROST1 field1 3 3.1 1.6×108 2.0×106 1.3%
PROST1 field2 1 0.9 9.3×107 1.7×106 1.9%
PROST1 field2 2 3.2 9.0×107 2.3×107 25.3%
PROST1 field2 3 5.6 6.9×107 8.5×105 1.2%
PBs recommended by only camera indicators
H&N4 field1 1 8.4 2.9×108 2.9×107 10.2%
H&N4 field1 2 2.7 1.8×108 3.2×105 0.2%
H&N4 field1 3 7.2 1.4×108 6.8×105 0.5%
PROST1 field1 1 1.9 1.8×108 1.1×107 5.9%
PROST1 field1 2 2.2 1.5×108 8.6×107 57.1%
PROST1 field1 3 8.2 1.2×108 4.2×106 3.5%
PROST1 field2 1 3.5 3.8×107 2.1×106 5.6%
PROST1 field2 2 0.5 1.4×108 2.8×107 20.4%
PROST1 field2 3 3.4 4.2×107 3.3×107 7.8%
PBs recommended by only camera indicators
H&N4 field1 1 12.1 1.9×108 4.6×107 24.2%
H&N4 field1 2 7.8 2.0×108 3.6×107 18.3%
H&N4 field1 3 11.7 2.4×108 1.2×106 0.5%
PROST1 field1 1 1.8 3.6×107 1.3×106 3.5%
PROST1 field1 2 5.2 1.5×108 3.9×107 25.4%
PROST1 field1 3 4.0 1.8×108 1.3×106 0.7%
PROST1 field2 1 8.5 5.1×107 4.8×106 9.5%
PROST1 field2 2 4.2 2.7×108 4.1×107 15.4%
PROST1 field2 3 4.3 9.5×107 4.6×107 48.8%
Table 6.4: Range mixing, accumulated statistics of the aggregated PBs, statistics of the
central PB in the initial TP and its corresponding percentage contribution to the aggre-
gated signal are given by ∆Range, Naggregation, Ncentral and c, respectively
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The clinical potential of proton therapy highly relies on the dose delivery precision. How-
ever, due to e.g. the semi-empirical conversion of the X-ray CT numbers into tissue stop-
ping power ratio (relative to water) along with patient positioning and anatomical changes,
the proton range in the patient has uncertainties. Prompt gamma is currently one of the
most promising technologies providing the possibility for in vivo and ideally real-time pro-
ton range verification. The accuracy of PG is affected by tissue heterogeneities, potential
inter- (and, although not addressed in this work, intra-) fractional anatomical changes as
well as the position of the PG detector relative to the patient, especially in the case of lim-
ited field-of-view systems like the first clinical prototype of a single slit knife-edge camera.
Moreover, detectability and reproducibility of the PG signal critically depends on sufficient
counting statistics, which is generally not guaranteed in a conventional treatment plan.
In this work, a so called PG emission indicator, consisting of the PG-dose correlation and
dose surface indicators, is proposed at the PG emission and treatment planning level to
identify the conformities between the PG and dose profiles as well as the sensitivities of
the PG-dose correlation to tissue heterogeneities. Additionally, the camera position indi-
cator proposed by (Huang 2020) is investigated to account for a realistic detector response,
including effects due to the counting statistics and the relative position of the camera and
PG signal falloff. All these indicators are tested on PBs of interest in the treatment plan
for four head and neck and one prostate cancer patients using both Geant4 and REG-
GUI generated dose and PG profiles. For the PG emission indicator, the shift differences
between the dose and PG emission distributions of the recommended PBs evaluated on
CTs at different time points (to capture anatomical changes) are within 1 mm for Geant4
datasets and less than 1.5 mm for 90% PBs simulated by REGGUI (with exceptions mostly
due to the application of the algorithm and machine learning model constructed based on
Geant4 datasets). The camera position indicator rejects PBs that are not centered in the
FOV of the above mentioned camera. Combining both indicators, only 2 PBs , located at
the edge of the area of the recommended PBs, were found to have more than 2 mm (max-
imum 4.5 mm) of difference between the falloff shifts of dose and detected/emitted PG on
the different CTs (REGGUI), due to comparably large anatomical changes at the Bragg
peak. Besides a few exceptions caused by unpredictable and comparably large anatomi-
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cal changes, the PG signals of most of the PBs recommended by the proposed indicators
are proven to be a reliable surrogate of the dose falloff at emission/detection level on the
same/different CTs, thus being suitable for proton range monitoring. Hence, the intro-
duced indicators are valuable to be used to identify and recommend reliable PBs for PG
based proton range verification, provided that sufficient statistics is available for a reliable
PG detection.
The Geant4 simulation used in this work shows that a precision of 1 mm in the PG sig-
nal detected by an ideal scoring plane outside the target (phase space data, see section
5.1) can be achieved at a PB proton statistics of 1.35×108, while the REGGUI simulation
including the slit-camera response shows that a 0.8 mm precision can be achieved at a
PB proton statistics of 2.00×108. These results are consistent to previous studies of (Xie
et al. 2017, Draeger et al. 2018). Only a few PBs can reach such a high statistics in con-
ventional TPs for typical fractionated proton treatments. To overcome this limitation, in
this work a method for boosting a few selected PBs above the statistics threshold while
not spoiling the TP was proposed and compared to other alternative approaches suggested
in the literature such as PB aggregation (Xie et al. 2017), which aggregates nearby PBs
of the initial plan to achieve high statistics. The re-optimized TPs are proven equivalent
to the initial TPs in terms of dose distribution, dose averaged LET distribution and TP
robustness with respect to anatomical changes, translational changes as well as range varia-
tions. The PB boosting method shows advantages over aggregation in terms of guaranteed
statistics, improved lateral resolution and reduced range mixing. Moreover, there is no
conflict between both approaches, as PG data of individual PBs could still be aggregated
regardless whether PBs are boosted or not.
With the results of this thesis, the in-vivo PG range verification method is taken into ac-
count in the MC proton TP for the first time, potentially contributing to a future reduction
of range uncertainties.
PG based proton range verification is based on the detected PG signal, which highly de-
pends on the PG camera. In this work, the camera response of a knife-edge slit camera,
which has been the first PG detector finding its way to clinical application, has been dis-
cussed. Further research could include the validation against other camera models, e.g.
Compton camera. This latter technology provides the possibility to monitor PG in 3D,
thus the 3D proton range information is possible to be monitored in the future. The pro-
posed approach in this thesis, so far applied to laterally integrated depth profiles, could be
further extended to fully account for a detected 3D PG signal.
In this work, PBs are identified and classified into three categories: 1. good PBs rec-
ommended by both PG emission indicator and camera position indicator, which in turn
reflect precise proton range information; 2. counter-indicated PBs, which are centered at
the FOV but do not allow to infer precisely the dose shift from the PG shift; 3. PBs which
are not centered in the FOV of the camera. When selecting the PBs to boost in a TP, good
PBs should be selected to provide reliable range information, e.g., for ruling out systematic
errors in the CT-range calibration or set-up errors. The counter-indicated PBs are usually
distributed in regions that are more sensitive to the anatomical changes, and could thus be
selected to provide valuable information on unexpected range errors due to such changes,
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although with less precise correlation to the delivered dose. More studies are needed to
further investigate the amount of information provided by the PG signal in relation to the
dose for the different categories, such that potential strategies, e.g. whether to trigger a
new CT or not, can be made correctly.
The next step should consider integration of the proposed method in treatment planning
platforms connected to treatment facilities equipped with PG detectors for a first experi-
mental proof-of-concept that the method proposed in this thesis can indeed enable more
reliable monitoring at both emission and detection level, e.g. in some controlled phantom
irradiation, prior to a later clinical deploymen
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